TW219928B - - Google Patents
Download PDFInfo
- Publication number
- TW219928B TW219928B TW080101540A TW80101540A TW219928B TW 219928 B TW219928 B TW 219928B TW 080101540 A TW080101540 A TW 080101540A TW 80101540 A TW80101540 A TW 80101540A TW 219928 B TW219928 B TW 219928B
- Authority
- TW
- Taiwan
- Prior art keywords
- alanine
- phenyl
- group
- nhch
- benzyl
- Prior art date
Links
- -1 pyrrolidinoyl Chemical group 0.000 claims abstract description 104
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 27
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 10
- 150000001408 amides Chemical class 0.000 claims abstract description 8
- 125000003277 amino group Chemical group 0.000 claims abstract description 7
- 150000001242 acetic acid derivatives Chemical class 0.000 claims abstract description 5
- 150000004677 hydrates Chemical class 0.000 claims abstract description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 101150047265 COR2 gene Proteins 0.000 claims abstract 2
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract 2
- 229960003767 alanine Drugs 0.000 claims description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 50
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- 239000000605 aspartame Substances 0.000 claims description 42
- 229960003438 aspartame Drugs 0.000 claims description 42
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 41
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 238000011049 filling Methods 0.000 claims description 19
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 17
- 235000011054 acetic acid Nutrition 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical group NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 11
- 239000007789 gas Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004989 dicarbonyl group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000004962 physiological condition Effects 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 4
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- HDWGBGKQLWCGNQ-UHFFFAOYSA-N aniline;formamide Chemical compound NC=O.NC1=CC=CC=C1 HDWGBGKQLWCGNQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- PRNLNZMJMCUWNV-UHFFFAOYSA-N 2-piperidin-1-ium-2-ylacetate Chemical compound OC(=O)CC1CCCCN1 PRNLNZMJMCUWNV-UHFFFAOYSA-N 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- KYDWLMOTNUUDAK-LURJTMIESA-N (3s)-3-amino-4-(2-methylpropoxy)-4-oxobutanoic acid Chemical compound CC(C)COC(=O)[C@@H](N)CC(O)=O KYDWLMOTNUUDAK-LURJTMIESA-N 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- IAOZJIPTCAWIRG-UHFFFAOYSA-N Methyl alpha-aspartylphenylalaninate Chemical compound OC(=O)CC(N)C(=O)NC(C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-UHFFFAOYSA-N 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 150000003943 catecholamines Chemical class 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000010102 embolization Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 abstract description 59
- 239000012453 solvate Substances 0.000 abstract description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 42
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- 230000008878 coupling Effects 0.000 description 27
- 238000010168 coupling process Methods 0.000 description 27
- 238000005859 coupling reaction Methods 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 235000004279 alanine Nutrition 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000002243 precursor Substances 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 14
- 229940073608 benzyl chloride Drugs 0.000 description 14
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 238000000354 decomposition reaction Methods 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 9
- 125000005518 carboxamido group Chemical group 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 229910052797 bismuth Inorganic materials 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 6
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 6
- YFNONBGXNFCTMM-UHFFFAOYSA-N butoxybenzene Chemical group CCCCOC1=CC=CC=C1 YFNONBGXNFCTMM-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- 241000286209 Phasianidae Species 0.000 description 5
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- 241000723353 Chrysanthemum Species 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical class IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- AXWKFRWLYPZEFQ-UHFFFAOYSA-N 3-oxobutanoyl chloride Chemical compound CC(=O)CC(Cl)=O AXWKFRWLYPZEFQ-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- ADSALMJPJUKESW-UHFFFAOYSA-N beta-Homoproline Chemical compound OC(=O)CC1CCCN1 ADSALMJPJUKESW-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- WOBLPDAWNVAVAS-UHFFFAOYSA-N butyl carboxy carbonate Chemical compound CCCCOC(=O)OC(O)=O WOBLPDAWNVAVAS-UHFFFAOYSA-N 0.000 description 2
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical group CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 2
- 229960005222 phenazone Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006308 propyl amino group Chemical group 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- RLIHXKPTGKETCC-QMMMGPOBSA-N (2s)-2-(benzylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NCC1=CC=CC=C1 RLIHXKPTGKETCC-QMMMGPOBSA-N 0.000 description 1
- DVVNPYAVFWSKAB-LURJTMIESA-N (2s)-2-(butylazaniumyl)propanoate Chemical compound CCCCN[C@@H](C)C(O)=O DVVNPYAVFWSKAB-LURJTMIESA-N 0.000 description 1
- XYXYXSKSTZAEJW-VIFPVBQESA-N (2s)-2-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 XYXYXSKSTZAEJW-VIFPVBQESA-N 0.000 description 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- VYCUBGGVCOABBL-LURJTMIESA-N (3s)-3-amino-4-butoxy-4-oxobutanoic acid Chemical compound CCCCOC(=O)[C@@H](N)CC(O)=O VYCUBGGVCOABBL-LURJTMIESA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SQBHGDSDVWCPHN-UHFFFAOYSA-N 1-methyl-3-phenylurea Chemical compound CNC(=O)NC1=CC=CC=C1 SQBHGDSDVWCPHN-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- WEBXRQONNWEETE-UHFFFAOYSA-N 2-(4-cyanophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(C#N)C=C1 WEBXRQONNWEETE-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- KMHQXYAFSZBESX-UHFFFAOYSA-N 2-chloro-2-phenylethanimidamide Chemical compound ClC(C(=N)N)C1=CC=CC=C1 KMHQXYAFSZBESX-UHFFFAOYSA-N 0.000 description 1
- MZVSTDHRRYQFGI-UHFFFAOYSA-N 2-chloro-4-methylpyridine Chemical compound CC1=CC=NC(Cl)=C1 MZVSTDHRRYQFGI-UHFFFAOYSA-N 0.000 description 1
- DKFPBXQCCCIWLC-UHFFFAOYSA-N 2-cyano-2-phenylacetic acid Chemical compound OC(=O)C(C#N)C1=CC=CC=C1 DKFPBXQCCCIWLC-UHFFFAOYSA-N 0.000 description 1
- IEEHKTFVUIVORU-UHFFFAOYSA-N 2-methylpropanedioyl dichloride Chemical compound ClC(=O)C(C)C(Cl)=O IEEHKTFVUIVORU-UHFFFAOYSA-N 0.000 description 1
- YTWYJCFQNOZVEC-UHFFFAOYSA-N 2-piperidin-1-ium-1-ylpropanoate Chemical compound OC(=O)C(C)N1CCCCC1 YTWYJCFQNOZVEC-UHFFFAOYSA-N 0.000 description 1
- YFNOTMRKVGZZNF-UHFFFAOYSA-N 2-piperidin-1-ium-4-ylacetate Chemical compound OC(=O)CC1CCNCC1 YFNOTMRKVGZZNF-UHFFFAOYSA-N 0.000 description 1
- IPXNXMNCBXHYLQ-UHFFFAOYSA-N 2-pyrrolidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCC1 IPXNXMNCBXHYLQ-UHFFFAOYSA-N 0.000 description 1
- BUUUUJNTECUTOP-UHFFFAOYSA-N 2-sulfonylbutanoic acid Chemical compound CCC(C(O)=O)=S(=O)=O BUUUUJNTECUTOP-UHFFFAOYSA-N 0.000 description 1
- LOQLDQJTSMKBJU-UHFFFAOYSA-N 4-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=C(C#N)C=C1 LOQLDQJTSMKBJU-UHFFFAOYSA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- NIDKGLRXRBFGEN-UHFFFAOYSA-N 4-cyano-2-methylbenzoic acid Chemical compound CC1=CC(C#N)=CC=C1C(O)=O NIDKGLRXRBFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- VQDQISMDUHBUFF-UHFFFAOYSA-N 4-phenylbutanoyl chloride Chemical compound ClC(=O)CCCC1=CC=CC=C1 VQDQISMDUHBUFF-UHFFFAOYSA-N 0.000 description 1
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- XUYVHYIOPPFDKG-UHFFFAOYSA-N C(C)(=O)O.N(F)(F)F Chemical compound C(C)(=O)O.N(F)(F)F XUYVHYIOPPFDKG-UHFFFAOYSA-N 0.000 description 1
- GTOSMKSIVZESGF-UHFFFAOYSA-N C1=CC(CCNC(=O)O)=CC=C1OCC(=O)OCC1=CC=CC=C1 Chemical compound C1=CC(CCNC(=O)O)=CC=C1OCC(=O)OCC1=CC=CC=C1 GTOSMKSIVZESGF-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 101100048447 Caenorhabditis elegans unc-4 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000252234 Hypophthalmichthys nobilis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SHWDJGOENIKENL-UHFFFAOYSA-N N-methyl-N'-(4-methylphenyl)methanediamine Chemical compound CNCNc1ccc(C)cc1 SHWDJGOENIKENL-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
- GWBWGPRZOYDADH-UHFFFAOYSA-N [C].[Na] Chemical compound [C].[Na] GWBWGPRZOYDADH-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- VHHCAGBVYBIOCK-LBPRGKRZSA-N benzyl (2s)-2-aminohexanoate Chemical compound CCCC[C@H](N)C(=O)OCC1=CC=CC=C1 VHHCAGBVYBIOCK-LBPRGKRZSA-N 0.000 description 1
- HDYQLGLEPPGPEV-UHFFFAOYSA-N benzyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OCC1=CC=CC=C1 HDYQLGLEPPGPEV-UHFFFAOYSA-N 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- RJJXSCQQRYCPLW-ZCFIWIBFSA-N butyl (2r)-2-aminopropanoate Chemical compound CCCCOC(=O)[C@@H](C)N RJJXSCQQRYCPLW-ZCFIWIBFSA-N 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QLVWOKQMDLQXNN-UHFFFAOYSA-N dibutyl carbonate Chemical group CCCCOC(=O)OCCCC QLVWOKQMDLQXNN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- BNSOYWDFFBDEFB-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O BNSOYWDFFBDEFB-UHFFFAOYSA-L 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prevention Of Electric Corrosion (AREA)
- Physical Water Treatments (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
f ριΓ^ί〇 五、發明說明 219928 ―本發明是有關新的醋酸衍生物,其製^,含有此化合物 的藥學製劑,以及這些化合物用以產製藥學製劑之方法。
Br. J· Cancer 60, 1989, 722 - 728 及 Exp· Cell Res. 179, 1988, 42 —49揭示具有Arg — Gly — Asp序列之天然及合成致肽。該 等歧狀據稱具有抑制血纖維蛋白原結合及血小板聚集作 用之活性,Br. j. Cancer 6〇,1989,^22 —似顯現靜 脈內杬轉移活性,可對抗肺腫瘤,延長受戚染小老鼠存 活·時間,Exp. Cell Res. 179,1988,42 — 49 亦顯示可 抑制人類黑色素腫瘤細胞黏著至血纖維黏佐素C fibronection) 及血纖維蛋白原之活性。 本-發明特別_是有關下式的醋酸衍生物 · H2N(NH) -C-X-Y-CO - Z-CHCQ,1 ) COOQ.2 (I) 其中 Q·1是氫、甲基或苯基, - . Q·2是氫、苯基一低碳烷基或低碳烷基,其可在生理條件 下被‘離, 、· X是1,4 —伸苯基,1,4 —伸六氫吡啶基,經由4 —位丨 置上的C原子與Y基團鍵結,或2,5 —或3,6_伸吡裤基 Y是下式基圃 (請先聞讀背面之注意事項再填寫本頁) «-· 打· 綠· 甲 4(210X 297-二'发) 3 五、發明説明( 219928 A6 B6 -(CH2)〇-2-CONHCH(Q3)(CH2)i-3- -CONHCH2CH(〇4)- -(CH2)2NHCOCH2- -NHCO(CH2)3-
Ο -C/V
\1/ νϊ/ Λ1/ \)/ 1 2 3 4 5 γ γ γ γ Υ ί\ /IV /wV /_V /1\ (請先閱讀背面之注意事項再璞"本頁) •泛.
(Y7) Υ6) ,打· •綠· 甲 4(210X297 \'发) 3a 9928 219928 雉濟部中夹详準局印裝 A6 B6 五、發明說明(2) _ 0Λ.是氫、甲基、苯基、-C〇〇H,-C00-低碳烷基, -CONH(CH2)2-COOH 或-CONH(CH2)2-COO-低碳烷基, 0/是氫、用基或苯基, . Z是1,4 一伸六氫吡畊基,1,4 一伸六氫吡啶基,經由 1 一位置上的N —原子鍵結至CO基團,寧下式基圃' -NHCHCR1)- ^ -NHCH(C〇R2)- · R1是氣、甲基、苯基或-COO-低碳烧基’ R2·是α —胺基羧酸*基團,經由其胺基或酯或醯胺鍵結 ,或下式基團-NHCH2CH2-Ar,或者 -C0-R2是任意的單一或二一低碳烷化的胺甲醯基.-,·或 吡咯啶醯基或六氫吡啶醯基, 苯基或可被下列取代之苯基:低碳烷基、低碳烷氧 基、-C00H、-C00-低碳烧基、-C00H, / -0(CH2) -C00-低碳烷基,-C0NH2-,-C0NH-低碳烷 基,-CON (低碳烷基)2,吡咯啶醯基或六氫吡啶醯基, 及其水合物或溶劑化物及生理上可利用的塩類。 於本發明內容中,tBii表示第三,丁基,B〇c表示第三 ,丁氧羰基、Z表示苄氧羰基、VaL表示L -異草胺酿 基、Phe表示L 一苯基丙.胺酿基、Ser表不L —餘胺酿基 、0Ly表示甘胺醯基、Ala表示L 一丙胺醯基、Asp表示 L_a —六冬胺醯基、Leu —百胺醯基且Tyr表示L _酪 胺醯基。 所謂“低碳”表示具1 一 6個,最好是1 一 4個碳原子 。低碳烷基的實例有甲基、乙基、丙基、異丙基及正—、 {請先閲磧背面之-意事項再填筠本頁) •装· .打· .味. f 4(21〇X ‘297 公,¾) 219928 A6 B6 五、發明說明(3 > _ . {請先閲讀背面之_注意事項再堪寫本页) 第二或第.三、一丁基。可在生理條件下^離的低碳烷基實 例有一級及二級低碳烷基。 有經由胺基屬結的《 —胺基羧酸基團實例有_ : VaL、
Phe、Ser、Leu、Tyr及其相當的低碳烧基或苯基一低 碳烷基酯、醢胺及單一或二一低碳烷基醯胺。 式I化合物可被溶劑化,特別是被水合化。本合作用發 生在製備過程,或是於式I最初無水化合物由於吸潮特性 而逐‘發生之中。 -· 式I化合物生理上可利用塩類之實例爲具有生理上可耐 受的無機酸的塩類,如氫氯酸、硫酸或磷酸,或具有璣酸 的塩類,如甲烷磺酸、醋酸、三氟醋酸、擰檬酸、延胡索 酸、琥珀酸或水楊酸。式I化合物也可與生物上可耐受的 鹸形成塩類。此種塩類之實例有鹸金屬、鹸土金靥、氨§ 烷基銨塩,如Na、K、Ca或四甲銨塩。式I化合物含有 甲脒基且因此可呈兩性離子型式存在。 式I化合物,其含有一個以上不對稱的C原子,以可對 映異構物,非對映立體兵構或其混合物型式存在,如4消 旋物。 較佳的式I化合物爲下化式 Μ洚部中衣搮準局印鉍 H2N(HN)C-X-Y* -CONHCHCRll)CH2COO(221 I-a 其中 ^ X是1,4~伸苯基或1,4 —伸六氣卩比P定基,經由4 —位 置上的C原子鍵結至Y·基團, γ·是下化式 ' f 4(210X 297^,¾) 五、發明説明(4 219928 A6 B6 -(GH^O-i-CONHCHCQ^i^)!^- -(CH2)2NHCOCH2- -NHCO(CH2)3- (γη) (Υ3) (Υ4)
(Y51) 經 濟 部 中 央 準 局 印 α*是氫或苯基, Ru 是氫或-CO-R22、' R22是α —胺基羧酸基團,經由胺基或其酯或醯胺鍵結, α21是氫或低碳烷基,其可在生理條件下被解離 於式I中,γ最好是化式Υ1基團,特別是 -CONH(CH2)2-4-/ . -CH2CONH(CH2)2-, ..-CONHCH(C6H5)CH2-, -CO> JHCH(CONHCH2CH2C(X)H)CH2-/ -CONHCH(COOH)CH2- 戎 -CONHCH(CH3)CH2-. 於式I中,Z最好是卞式基團:-NHCH2-,-NHCHCCHO ,NHCH(CeHs)-,-NHCH(COO·異丁基)-, -NHCH(CO-VaL)-,-NHCH(CO-Phe) -,-NHCH(CO-Tyr)-,乙NHCH(CO-Ser-OC2H5)-,-NHCH(C0-Leu-0-異丙基)-, -NHCH(CONHCH2CH2-C6H4-〇CH3 ) - » -NHCH(CONHCH2CH2- CeH4-COOH)- , -NHCH(CONHCH2CH2-CeH4-〇CH2COOH) - » -NHCH(CONH2-)或-NHCH (吡咯啶醯基)一0 特別佳的式I化合物爲下列: ' {請先聞讀背面之^意事項,再填荈本页) •装· •訂· .綠· 甲 4(210X 297 公沒) 6 五、 (5
N
C .N 鲮基〕 219928 A6 B6 組濟部中央搮準局印製 〜〔N —(對位一甲脒基苄醯基)一 P —丙胺 〜α —天多胺醯基〕一 3 —苯基一 L 一丙胺酸, 、〔4 一(對位一甲脒基苄醯胺襄)丁醯〕一 酸基〕一L 胺酸, 〜(對位一甲脒基苄醯基)一i8 —丙胺醯〕- 〜〔N —(對位一甲脒基苄醯基)一卢一丙胺 〜《 —天冬·胺醯〕一 L 一百胺酸異丙基酯, 〜〔N —(對位一甲脒基苄醯基)一/3 —丙胺 〜《—天冬胺醯〕一L 一無1草胺酸,〜 〜〔N —(對位一甲脒基苄醯基)一Θ —丙胺 〜α —天冬胺醯〕一3 —(對位羥苯基)一L 〆 〜〔5 —(對位一甲脒基苄醯胺基)戊醯基〕 〜天冬胺酿基〕一3 —苯基一 L 一丙胺酸, 5〜(對位一甲脒ΐ苄醯胺基)戊醯基〕一 L 一
L N
L ^冬胺 N〜〔N P〜丙咹酸 N〜〔N 鷗基〕〜L N -鷗基 N - 醚棊〕〜L 〜丙胺酸, C N α Ν L Ν •I _ Ν a 天冬胺酸 異丁基酯, 〔Ν-〔 ν—(對位一甲脒基苄醯基)一卢一丙胺 酿基〕一L~a —天冬胺醒基〕一L 一絲胺酸乙基酯及 & —〔 N ~〔〔( R ) — 1 —(對位一甲脒基苄醯基) —3 —吡咯啶基〕’一羰基〕一L — «—天冬胺醯基〕一 3 一苯基一L一丙胺酸。 式I化合物進一步的實例有下列: N_〔N —〔N — ( 1—甲月米基一 辦 4二六氫吡啶基Λ) {請先聞讀背面之"意事4再瑱寫本頁) 甲 4(21〇Χ 297公沒) 7 928^19928 A6 B6 五、發明説明(6 卢一丙胺靡基〕_L_a_天冬胺酿基〕—3 —苯基一 L 一丙胺酸, N._〔 N — _〔 N —(對位一甲脒基苯基乙醯)一—丙 胺酿基〕一L — α —天冬胺酿基〕一 3 —苯基_.L 一丙胺 酸 N —〔 N —〔 4 一(對位一甲脒基苯基胺甲醯基)丁醯 基〕一L — α —天冬胺酿基〕一 3 —苯基一L 一丙胺酸, N _〔 N —(對位-φ雠基苯基胺甲醯基)乙醯〕一L — α —天冬胺醯基〕一 3 —苯基一 L 一丙胺酸, 外消旋一 Ν — ( 1 -對位-甲脒基苄醯基)一3 —六氫吡 畊基一羰基〕一Ρ —丙胺酸, Ν —〔 4 一(對位一甲脒基苄醯胺基)丁醯基〕一/3 — 丙胺酸 請先閱讀背面之注意事項再填"本苜) Ν 〔(DL) Ν (對位_甲脒基苄醯基)一 3 —苯 經濟部中央搮準局印裝 〔3 — ( 1 —甲|米基一4 —六氣 基一/3 -丙胺醯基〕一/3 —丙胺酸, Ν,Ν —〔〔( S )-(對位一甲脒基苄醯胺基)伸乙基 〕二羰基〕二一/3 -丙疲酸, 2 — Ν _ (對位_甲脒基苄醯基)一4— Ν —( 2 —羧乙 基)一L 一夫冬酿胺, Ν —〔 5 —(對位一甲脒基苄醯胺基)戊醢基〕_/3 — 丙胺酸, 外消旋_ Ν 吡啶基)丙醯基〕一3 —六氫吡啶基〕羰基〕一0 —丙胺 酸, 甲 4(210X 297'/:^) 8 A6 B6 21D928 五、發明説明(7 ) (請先閱讀背面之.注意辜渊再瑱穷本页) N_〔〔( S ) — 1 —(對位一甲脒基苄醯基)一 2一 吡咯啶基〕乙醯〕—P —丙胺酸, (-S ) — 〔〔N —(對位一甲脒基苄醯基)一卢一 丙胺醯基〕胺基〕一3~〔(對位一甲氧基苯乙基)胺甲 醯基〕丙酸, N —〔〔( R ) — 1 —(對位_甲脒基苄醯基)一 3 — 吡咯啶基〕羰基〕一Θ—丙胺酸, N二〔N —(對位二甲脒基苄醯基)一 2 —甲基一卢一 丙胺酿基〕一 L — o: —天冬酿胺, N —〔 N -〔(對位一甲脒基苯基)乙醯〕一0 —-丙胺 醯〕一P —丙胺酸, 外消旋一N —〔〔〔 1~(對位一甲脒基苯基)乙醯〕 一 3 —六氫吡啶基〕一羰基〕一Θ —丙胺酸苄酯, 一 外消旋一N —〔〔 1 一〔(對位一甲脒基苯基)乙醯〕 —3 —六氣卩比唆基〕一幾基〕一 jS—丙胺酸, • .· _N 〔 N-〔N-〔3— ( 1-甲脒基一4 -六氫吡啶 基)Λ〕一卢一丙胺醯基〕一L 一 α—天冬胺醯基〕一3 —苯 基一 L 一丙胺酸, (S ) - /3 _〔〔 DL.—. Ν —(對位一甲脒基苄醯基)一 3 —甲基一/3 —丙胺醯基〕胺基〕氧基一 1 一吡咯唆 經 丁酸, ‘‘ 濟 f DL —N —〔N—(對位一甲脒基苄醯基)一Θ —丙胺醯 g 基〕一 3 —甲基一/3 —丙胺酸, φ 為 Ν —〔D4— Ν—(對位一甲脒基苄鉍基)一2 —苯基 f 4(210Χ 297 9 219928 A6 B6 五、發明説明(8 —卢一丙胺醯基〕一卢一丙胺酸, DL — N —〔 N —(對位一甲脒基苄醯基)一 P —丙胺醯 基'〕·一2 —甲·基一卢一丙胺酸, - DL —Ν —〔 Ν —(對位一甲脒基苄醯基)_ Ρ —丙胺醯 基〕一 2 —苯基一卢一丙胺酸, 對位一〔2—〔〔Ν —〔Ν—(對位一甲脒基苄醯基)* -卢一丙胺醯基〕一 L — α —天冬胺醯基〕胺基〕乙基〕 rrr ir 人 、, 本甲酸, DL —N—〔 N —(對位一甲脒基苄醢基)一 # 一丙胺醯 基一 3 —苯基一卢一丙胺酸, · :· 〔對位一〔2 —〔〔N-〔N_(對位一 )一|9 一丙胺醯基〕一L_« —天冬胺醯基 〕苯氧基〕醋酸, 1 —〔 N—(對位一甲脒基苄醯基)一戶 一 4 一六氣批唆基醋酸, 4 —〔 N—(對位一甲脒基苄醯基)一戶 —1 —六氫吡畊醋酸及 N_〔N —〔N —〔( 5 —甲脒基一 2.—吡啶基)羰基 〕一卢一丙胺醯基〕一丄+ ― « —天冬胺醯基〕一 3 —苯基 一 L —丙胺酸。 經濟部中央捃準局印裝 甲脒基苄醯基 〕胺基〕乙基 一丙胺醯基〕 一丙胺醯基〕 its 先 閱 讀 背 之 事 Λ 再 填 % 本 百 上述化合物之獲得可依據本發明,自下式化合物中解離 至少一個保護基而得
Xf-X-CO-Z'-CH(al) -CGO-Q5 Π 其中 甲 4(210X 297W 发) 10 - 219928 ^ 五、發明説明(9 ) (21.及Y具進一步所定義的意義, X’是苯基或六氫吡啶基,其在4 一位置上可被任意保 護的甲脒基所取代,且 及具如上述z及(22之相同意義,或者, 將下式膪中之腈基轉化成甲脒基 (Vi c Ό-ν- co-ζ -c π(αή-cco-q ^ ·(III) 且必要時,將式I化合物轉化成一個生理上可耐受昀塩, 或者將式I化合物之塩轉化成游離酸或鹸。 於式Π化合物中之保護基買例有苄基或低碳烷基h如第 三·、丁基,含於酯基、苄基-oco-或第三、丁基-oco-,· 及甲脒保護基,如Z及Boc。經保護甲脒基之實例有 -C_)NH-Z,-C(NH)NH-Boc 及-C(N-Boc)-NH-Boc 。一 酯基可以本身已知之方式解離,如利用鹼水解,如鹸金 屬氫氧化物,如氫氧化鈉,於溶劑中如甲醇。苄酯類可於 貴金屬催化劑存在下以氫化作用解離,如钯於碳(Pd/c ) 於溶劑中,如甲醇、乙醇、甲酸或醋酸,溫度高達約40X: ,最好在室溫下。於此製法中,除在於基.團t中之甲脒基 a 保護基,如Z,以相同方.式除去。 班洚部中衣搮準扃印裝 請先«lii背面之注意事項再填寫本页) •打· 酯基,如第三、丁基,或甲脒基保護基,如Bo c,可例 如以酸予以解離,如甲酸或三氟醋酸,必要時於溶劑中, 如二氯曱烷,在高達40°C之溫度下,最好在室溫下。 式II化合物爲新的,且因此爲本發明的一個主題。其製 備可以本身导知之方法始自已知化合物,如下所述。 f 4(210X 297W 发) 11 - 219928 五、發明說明(10 ) _因咕,.第一步驟是下式之胺 H-Z,-CHCQ/)COO-Q_22 與下式之酸偁合 r5-NHCH(Q31)(CH2)i-3-C〇〇H Va r5-NHCH2CH(Q4)-CCX3H Vb A6 B6
IV COO Η
Vc .COO Η
Vd
Ve VI 其中 (T2是個容易被解離的烷基, α31是氫、甲基、苯基、-COO-低碳烷基,或 -CONH(CH2)2.-COO-低碳烷基, M洚部中夹搮if局印裴
• COOH R5是胺基保護基,如z或Boc, η 是=〇 或 P=3,或 n = 2 且 P=1, 以鈦化學本身已知之方法形成醯胺基。 因此,可進行IV與Va、Vb或VI之’偶合,如於四氫吱 f 4(210X2971、沒) -12 - A6 B6 219928 五、發明説明(11 ) . 請 先 磧 背 之 •注 意 事 •項 再 填 寫 本 页 if中(THF ),由一KTC至室溫,在氬氣下及鄰位—苯並 .三唑一1 -基一N,N,N',lsr-四甲脲六氟磷酸醚(HBTU ) 存在下。IV與Vc、Vd或Ve之偶合可達成,-如最初於 TWF中利用氯二甲氧三考及Ν 福作活化酸Vc、Vd或 Ve,之後以胺IV的對位一甲苯磺酸酯及N -甲基嗎福4 反應產物。 · 自如此獲得的反應產物中,胺基保護基R5,如ZSB〇c ,可再依上述選擇性地'除去,利用催化氫化作用或利用三 氟醋酸。 下式之胺 . -:·
H2NCH(Q,31 ) (CH2) ,-3-C0-Z, -CHCQ.1 )COO-Q.22 VIII 打 以此方式獲得,如始自IV及Va,可與4 —氰基苯甲酸或 4 一氰基苯基醋酸偶合生成腈,如式〖Π之一,如上所述以 Va偶合IV。 線 以此方式獲得的腈或由IV及VI偶合而得的腈,可轉化 成化合物II,其中含一個游離的甲脒基,如將硫化氫與 三乙胺於吡啶中反應,生成硫醣胺,於丙睡中將甲基碘甲 基化且再於甲醇中與醋酸胺反Μ。腈ΠΙ.可類似地轉化成 相當的式I化合物。-· Μ濟部中央搮準局印^ 上式VIII之胺也可與如1 一甲脒基一 4 一六氫吡啶羧酸 ,對位一甲脒基苯乙醯基氯或對位一甲脒基苄酿氯反應, 生成Π化合物,其中X是1 —甲脒基—4 一六氫吡啶基或 對位一甲脒基苯基。 式VIII之胺或始自式IV化合物及酸的k Va至Ve胺,可 甲 4(210X 297 公;Ϊ) A6 B6 219928 五' 發明說明(12 ) {請先Μ讀背面之"意再求寫本瓦) 進一步於二氯甲烷/碳酸氫鈉水溶液中與對位一甲脒基苄 醣氯反應,接下來於碳酸鈉存在下與氯甲酸苄酯或與二碳 酸二第三,丁基酯反應,以生成式Π化合物,-其中t是對 位一甲脒基苯基而被Z或Boc所保護。 式IV — VI化合物是已知的,或者可以類似已知化合物 方式製備,或如下實例所述破備。 .. 因此,腈VI可由式NCCeh (CH2)e-NH2之適當胺與式 HOOC(CH2)p-CGOQ/「之適當酸偶合而製備,如類似胺IV 與酸V之偶合,再除去酸基Q22。 欲製備式Π化合物,其中xf4 —六氫吡嗥基,在位 置上被一個經保護的甲脒基所取代,式 IX 一 可先與如—雙一(第三,丁氧羰基)一 s —甲基異 • ·. 硫脲反應,於第三.,丁醇及氫氧化鈉溶液中,生成下式之 - 化合物 B〇c-W=C^-B〇c)^T^CH:LCHl- COOH x 後者可再與如下式化合物偶合 綏濟部中夫详泽扃印裝 ii2NCH (Q31) (CH2) i-s-CONHCHjCHjCOOCHzCkH. XIa • * · * 身.♦ H2NCH2CH (Q4) conhch2ch,cooch2c6h5 xib f 4(210X 297^,¥) 14 - 219928 五、發明說明(13 ) A6 B6 Ηί> conhc^ch^cocch^ XIc
-COMHCHVCW^COOOHg
Xld (S)
Xle {請先Μ讀背面之,注意事邛再填寫本页) -装· 其中 〇_31是氫、甲基、苯基、-coo-低碳炫基或 -CONH(CH2)2-COO-低碳烷基0 一 •打. 式Π的化合物,其中t是苯基或4 一六氫吡啶基,其在 4 一位置上被經保護的甲脒基所取代,可附加地製備即將 式X,-Y-COOH的酸與上式IV之胺偶合而成。 .線· 式I化合物,其溶劑化物及其塩類,可抑制血嫌維蛋白 原、織維網蛋白二f,以及威利伯德(w.illebrand )因子 與血小板糨維蛋白原受-體.之結合(糖蛋白lib / ffla ),及 . 其與其他粘附蛋白質,如外網蛋白(Vitronectine ),膠 / 經 濟 部 中 央 搮 準 局 印 裝 原蛋白及昆布胺酸等與不同細胞型態表面上之相當受膛之 結合。該化合物如此影響細胞一細胞及細胞基質之交互作 用。其特別可預防血小板血栓之形成,且可用於控制或預 防血栓形成7腿栓塞、心肌梗塞、發炎、及動脈硬化等疾 f 4(210X 297^'^) 15 - 219928 ^、發明説明( 病。這些化合物對於腫瘤細胞也有作用,因其可抑制其轉 移的形成。其也可t抗瞳瘤劑應用。進一步有劢於傷口之 癒 '合。. -._ 於血纖維蛋白原受髖,螗蛋白lb / Ha,上抑制血殲維 蛋白原之形成可诶下述侦'測 糖蛋白lib / IDa_之獲得是以/TritoQ Χ-Ιαο萃取人類血小 板,再以外源凝集素親和力層析純化(Analytical Bio chemistry 151,Γ985, 169-171 )並於 Arg-Gly-Asp-Ser 親和力,柱上層析(Scien ce 231, 1986, 1559-62 )。 如此獲得的受體蛋白質再結合至微滴定盤。血纖維蛋原 之特異結合至經固化的受.體,可藉ELISA系統之助決定 (“酵素一鏈結之免疫吸附分析法”)。以下的ICse値相 當於受試物質之濃度,其係抑制血嫌維蛋白原與經固化受 體50%結合所須之濃度: ί請先'"讀计面一之:1/事明策裘本瓦 經•濟部中央秣準局印裝 得自實例 之產物: 1 2 · 3 4 5 6 7 1C» (EM) 0.0003 0.13 0.045 0.035 0.01 0.01 0.Q27 得自實例之產物: 8 9 10 11 18 25 28 31 38 39 ΙΟ» (π«) 0.10 0.005 0.022 0.0025 0.01Q 0.0067 0.005 0.0128 0.0036 0.0012 A6 B6 219928 五、發明説明(15 ) - · _ * {請先聞讀背面之注意事項再填寫本頁) __如先前-所示,本發明是有關含有式I化合物,其溶劑化 .物或其塩類的醫藥品,且進一步是有關產製此型式藥品之 方法·,其特徵在於將一種以上的該化合物及必要時的一種 以上其他治療上有用的物質做成藥學投予劑型。藥品可經 腸投予,如口服呈錠劑.、膜錠、衣錠、硬及軟明膠膠囊劑 、溶液劑、乳劑或懸液劑,或經直腸地,如呈栓劑,或噴 霧劑。然而投藥也可採用腸外方式,如呈注射溶液劑或浸 劑。' 欲製備錠劑、膜劑、衣錠、及硬明膠膠囊劑時,活性化 -合物可與藥學上惰性、無機或有機賦形劑混合。乳塘·.、玉 米粉或其衍生物、滑石、硬脂酸或其塩類,可爲錠劑、衣 錠及硬明膠膠囊劑此型式之賦形劑。如植物油、蟠、脂質 、半固體及液體多元醇,則適合當軟明膠膠囊劑之賦形劑 - .· ' ;然而,依據活性化合物之本質,於軟明膠膠囊中根本不需 要賦形劑。如水、多元醇、蔗糖、轉化糖及葡萄糖,則適 * 於產製溶液劑及糖.獎劑時當賦形劑;水、醇類、多元醇、 甘油及植物油適合於注射溶液劑;而自然的或硬化油、蠟 、脂質及半固|g或液髖多元醇適合於栓劑.。藥學製劑可另 外含有保藏劑、增溶劑'稳定劑、沾濕劑、乳化劑、甜昧 劑、著色劑、芳香劑、變化等滲壓力之塩類、緩衝物質、 4 包衣或抗氧化劑。 欲控制或預防上述之疾病,活性化合物之劑量可在大範圍 內變化,且自然必須適合每一個別例子中之個別狀況。一 - · 般而言,於口.服時,約0.1至20¾克/公斤之劑量,最好 甲4(210X 297乂廣) -17 - 219928 A6 B6 組濟部中衣搞率扃印來 五、發明說明(16 ) 悬約0.5至4毫克/公斤(每天)可適用於成人,然而, 若證之有效也可超出上示之上限。 實例~ 1 15毫升的三氟醋酸加至1〇〇毫克N —〔 N —〔N —(對 位一甲腺基苄醣基)一.卢一丙胺醣〕一 3,(第三,丁氧 羰基)一L —丙胺醯基〕一3-苯基一L —丙胺酸第三, 丁基^氫碘酸塩於10毫升二氯甲烷之懸液中。於室溫下3 小時後,溶劑蒸發且殘'留物以乙醚結晶。經甲醇/乙酸乙 酯再結晶後,可得32毫克的Ν —〔 Ν —〔 Ν —(對位一甲 -脒基苄醯基)一卢一丙跨醣基〕一 L—天冬胺醯基〕一 3 一苯基一L—丙胺酸三氣醋酸酯,m.p. 216 — 220 eC (分解)。 起始物質製備如下: - ⑻834毫克HBTU及0.24毫升N —甲基嗎福在〇 之氬氣下加至446毫克Z —卢一Ala - OH及785毫克 Η — Asp ( Ο — tBu ) — Phe — 0 tBu (由 Z — Asp (0 — tBu ) — OH 與 H — Phe — 0 — tBu 縮合,再行氫解 作用而得)之溶液中。5小時後,混合物.縮合,殘留物分 配於乙酸乙酯/ 5 % NaHC03中。有機層以水及1M KHSCh 洗滌。乾燥有機萃取物、過濾再濃縮。殘留物自乙酸乙酯 /二異丙基醚中再結晶,可得392毫克的Z —^一 Ala-Asp ( O - tBu ) - Phe - Ο-tBu > m.p.138 — 139 °C° (b)欲於乙醇中及i〇 % Pd/c存在下,行前艇體(550毫 克)之催化氫化作用,於是在矽膠上利用乙酸乙酯/甲醇 (請先聞讀背面之注意事項再填寫本页) k. .打· f 4(210X2971'«) 18 A6 B6 219928 五、發明说明(17 ) (請先聞讀卄面之-意事項再填寫本頁) 4_: | — 1 : 1 層析,可得 417 毫克的 H-P-Ala-AspCO- tBu) -Phe-O - tBu , MS : 464CM+H ) + 〇 (ch藉著以實例⑻所述之方式,將350毫克(b)-產物與125 毫克4 —氰基苯甲酸偶合,再經矽膠上以乙酸乙醒層析後 ,可得293毫克的N-〔 3—(第三,丁氧羰基)一N — 〔N—(對位一氰基苄醢)一 0 —丙胺醯基〕一丙胺 醯基〕一 3 —苯基一L 一丙胺酸第三,丁基酯,m.p. 74 -76。(:。 … ⑹270毫克前軀ft於15 : 1吡啶/三乙胺之溶液,以硫 化氫飽和。24小時後除去溶劑,且殘留物分配於乙酸乙酯 / 5 % NaHC03中。有機萃取物以水及i Μ硫酸氫鉀洗滌 ,乾燥再濃縮。殘留物於矽膠上利用乙酸乙酯層析,再自 己烷中再結晶,可得230毫克的Ν-〔 3 —(第三,丁氧 羰基)一Ν —〔 Ν —(對位一硫胺甲醣基苄醯基〕一沒一 丙胺醯基〕一 L 一丙胺醱基〕一3 —苯基一 L 一丙胺酸第 三,丁基酷,m.p. 101 — 103*C。 班 濟 部 中 央 橾 準 局 印 裝 ⑻2毫升的甲基碘加至200毫克前躯ϋ於15毫升丙酮中 之溶液中》經沸騰溫度下3小時後,令混.合物冷却至室溫 ,產物加二乙醚沈澱。可得226毫克的Ν —〔 3 —(第三 ,丁氧鞭基)一Ν—〔 Ν —〔對位一 1 一(甲硫基)亞胺 甲醯基〕苄醯基〕一沒一丙胺醯基〕一 L_丙胺醯基i — 3 —苯基一 L —丙胺酸第三,丁基酯氫碘酸塩,m.p· 139 -140 °C 0 (f) 32毫克的醋酸銨加至160毫克前軀體於10毫升甲醇之 甲4(210X297公发) 19 - 219928 A6 B6 五、發明议明(18 ) {請先間讀背面之¾意事邛再填艿本頁) 垮笮中。.反應混合物保持在沸騰溫度下4小時。經冷却至 室溫後,過谳溶液,濃縮,再以二乙醚處理。濾出沈激的 產物並乾燥。-可得135毫克的N-〔N —〔 N_-(對位一 甲眯基苄醯基)甲胺醯〕一 3 —(第三,丁氧羰基 )一 L —丙胺醯基〕一3 —苯基一 L 一丙胺酸第三,丁基 酯之氫碘酸塩,m_ p · 162 — 163 °C。/ . 實例2 藉著於二氣甲烷中以'三氟醋酸處理,如實例1所述,並 且自甲醇/二乙酸中結晶,可自60毫克的N —〔 N — Γ N -_ (1 _甲脉基~ 4 —六氣批唆基稷基)一β —丙胺择基 〕一 3 —(第三,丁氧羰基)一L 一丙胺醯基〕_3 —苯 基一L —丙胺酸第三,丁基酯,獲得26毫克的Ν —〔 Ν — 〔N — (f邪脒基一 4 一六氫吡啶基羰基)一0 —丙胺醯基 〕一 L-α —天冬胺醯基〕一3—苯基一 L 一丙胺酸三氣 醋酸塩(2:3 )。 起始物質如下製備: 將86毫克的1 一甲脒基一4 一六氫吡啶基羧酸(Be lg. Pat. 893, 282, Nippon Chemiphar Co.Ltd.)與 119 毫 克的 H-^-Ala - Asp ·( 0- tBu ) — Phe - 0- tBu (實 例lb)於二噁烷中,及58毫克吡啶塩酸塩存在下,依實例 1⑻之方式偶合,再於矽膠上利用二氯甲烷/甲醇1:1層 析,可得71毫克的Ν —〔N —〔N —( 1一甲脒基一4一 六氫吡啶基羰基)一/3 —丙胺醯基〕一 3—.(第三,丁氧 羰基)一L 一丙胺醯基〕一 3 —苯基一 l 一丙胺酸第三, f 4(210X 297乂沒) -20 - 雉濟部中央揲率扃印鉍 A6 _2.19928_ B6 -_ 五、發明説明(19 ) . · 7;棊酯,MS : 617 ( M+H )+。 實例3 藉·著如實例1所述般,以三氟醋酸處理,可-自50毫克的 N —〔 N-〔 N —(對位一甲脒基苯基乙醯基)一卢一丙 胺醯基〕一:i (第三,丁氧羰基)~L "丙胺酷基〕一 3 —苯基一L —丙胺酸第三,丁基酯氫碘酸塩中獲.得36毫克 的N —〔 N —〔 N —(對位一甲月米基本基乙酿基)一β — 丙胺醯基〕一L — «二-天冬胺醯基〕一 苯基一 L 一丙 胺酸之三氟醋酸塩,ni.p. 218_ 220°C (自二乙醚)° 起始物質如下製備: ⑻以142毫克的4 一氰基苯基醋酸與371毫克的H -卢 -Ala-Asp-(0-tBu)-Phe-0-tBu(^ 例 lb )偶合,以實例 1 ⑻所述方式,自矽膠上利用乙酸乙酯/甲醇層析後,可得 250毫克的N —〔 N —〔 N —(對位一银基本基乙睡)一 戸一丙胺醯基〕一 3 —第三,丁氧羰基一 L —丙胺醯基〕 —3-苯基一L—丙胺酸第三,丁基酯,m.p. 93’一94 •C。 (b)將230毫克上述實例1⑹之前軀體硫.化,再於矽膠上 . 利用乙酸乙酯層析,可得.160毫克的N —〔N-〔N—( 對位一硫胺甲醣基一苯基乙醯基)一 P —丙胺醯基〕一 3 一第三,丁氧羰基一L—丙胺酿基〕一 3—苯基一L 一丙 胺酸第三,丁基酯,MS ·· 607 (M + H)+。 ⑹以類似實例1⑼,甲基化120毫克的前躯體,再經結 晶化作用可得100毫克N —〔 N —〔 N -(對位一甲硫基 甲 4(210X 297公沒) —21 — {請先聞讀背面之/i意事項,再填寫本頁) k. •打. 219928 A6 B6 五、發明說明(20) 51胺甲醯基)苯基)乙醯基〕一卢一丙胺醯基〕一 3—第 三,丁氧羰基一 L 一丙胺醯基〕一 3 —苯基一 L—丙胺酸 第三·,丁基酯·氣碘酸塩,m. p . 1〇3 - 1〇4。(:(丙酮/二 乙醚)。 ⑹依實例1⑺,以醋酸胺反應90毫克的前軀體,可得62 毫克的N-〔 N —〔 N-(對位一甲肤基苯基乙睡基)一 /3 —丙胺醣基〕一 3 —第三,丁氧羰基一 L 一丙胺醯基〕 一 3 —苯基一 L —丙疲酸第三,丁基酷氫碘酸塩,m.p. 152 t (甲醇/二乙醚)。 實例4 ·· :· 依實例1所述,以三氟醋酸處理55毫克的N —〔 N —〔 4—(對位一甲眯基苯基胺甲醯基)丁醣〕一 3—(第三 ,丁氧羰基)一 L 一丙胺醣基〕一 3 —苯基一L—丙胺酸 第三,丁基酯氫碘酸塩,可得31毫克的N_〔 N —〔 4一 (對位一甲脒基苯基胺甲醯基)丁醯〕一 L 一天冬醯 ·· 基〕_ 3 —苯基一Λ —丙胺酸三氟醋酸塩(5:4 ), m. p . 159 — 161 °C,且此係經自乙醇/二乙醚結晶化作 用後而得。 起始物可如下製備:-.· ts. 部 搞 率 JS] 印 ⑻依實例1⑻所述,偶合1 · 18克的4 一胺基苄腈及 1.25 毫升戊二酸單申酯,自乙酸乙酯中再結晶後可得 1.83克的4 一〔對位一氰基苯基)胺甲醯基〕丁酸甲酯 » m.p. 126 - 127 eC ° (b) 6毫升的.氫氧化鈉1 N溶液,加至1克前軀皚於丨0毫 22 {請先聞讀背面之•注意事邛再填寫本百) f 4(21〇X 297^'^) 2i992d A6 B6 五、發明說明(21) · 升甲醇之·溶液中。7小時後,澳縮反應 - · ' . 乙酸乙酯萃取,萃取物再用1 N氫氯酸 殘留·物,以水.洗再乾燥。可得575毫克 基苯基)胺甲醯基〕丁酸,m.P. 200 -(C)依實例1⑻所述,將464毫克的前 H-Asp(0-tfcu)-Phe-0-tBu 偶合,自矽 析,並再於己烷中攪拌後,可得701毫 混合物,殘留物以 中和。濾出生成之 的4 _乂對位一氰 -201 °C 〇 軀體與863毫克的 膠上以乙酸乙酯層 竞的N —〔 3 —( 第三·,丁氧羰基)一N_ —〔 4 —(對位一氰基苯基胺甲醯 基)丁醯〕一L 一丙胺醣基〕一3 —苯基一 L—丙胺酸第 三,丁基酷,rn.p.64 — 66 t。 ..... ⑹以類似實例1 (d)之方式,將350毫克的前軀體與硫化 氫反應,可生成304毫克的N —〔 3 —(第三,丁氧羰基 )-N - [ 4 甲胺酿基〕一 178 — 179 °C ⑼以實例1 用二匕基醚结 一(對位一硫胺 3 —苯基一L — ,此並 ⑻之類 晶後, 經乙酸乙 似方式將 得到175 羰基 N - 〔 4 —〔 對 甲醯基苯基)丁醯〕一L 丙胺酸第三,丁基酯,m.p. 酷再結晶。 15〇毫克前驅物甲基化,使 毫克N —〔3 一 C第三丁氣 1 一(甲基硫基)甲脒基〕 ......................................................^........................................................^ {請先聞讀背面之注意事項再縝寫本頁) * 笨基〕胺甲醏基〕丁 L -丙胺酸第三丁醏碘醆鹽( 战基.一 L 一丙胺醢基〕一 3 _笨基一 經濟部中央揉準局印仗 (f)以實例1⑺之類似方法, 〔4 —(對位一 三,丁 基
L 丙胺酸第 氧羰基〕 ,丁基酷 1 : 1 ),熔點 127 - 128 *C。 自克前軀鰱可獲得60¾克 甲月米基苯基胺甲醯基)丁醯 ~L~丙胺醯基〕一3 —苯 氣碘酸 i,m . P . 1 30 - 1 32 A6 B6 219928 五、發明説明(22) . ·. •C。 (請先«讀背面之U意事邛再填窵本页) 實例5 反-應100毫-克的N —〔 N -〔(對位一甲脒基苯乙基胺 甲酿基)乙酿〕一 3 —(第三,丁氧療基)一 L 一丙胺酿 基〕一 3 —苯基一 L 一丙胺酸第三,丁基酯氫碘酸塩與三 氟醋酸,依實例1所述,目二乙醚中結晶化後,·可得69毫 克的N —〔 N —〔(對位一甲脒基苯乙基胺甲醯基)乙醯 〕一 L — α —天冬胺醯·〕一3 —苯基一L —丙胺酸三氟醋 酸塩,m. p · 141 - 143 ·(:。 起始物質可如下製備: _ . ·,:· ⑻370毫克的對位一(2 —胺基乙基)苄腈,MS : 147 (M + H)+,可得自8 76毫克的對位一氰基氧化肉桂酸 (pharmazie 28,1973,724.)利用已知之反應次序 一 (Organic Synthesis 51, 1971, 48 )。 (b) 0.59毫升的甲基丙二醯氯於5毫升THF之溶液,在 一 10 °C下逐滴加至.731毫克對位~( 2 —胺基乙基)苄膪 及1· 39毫升三乙胺於10毫升THF之溶液中。再令混合物 加溫至室溫,倒入冰水再以1 N氫氣酸調至PH*。THF蒸 發,且水性萃取物以‘乙酸.乙酯萃取。經乾燥及濃縮後,可 得380毫克的(對位_氰基苯乙基)丙醯胺酸甲酯,m.p. 125 °C ° ⑹以類似實例4 (b)之方法,水解75〇毫克(b)產物,可得 365毫克的N -(對位~~氰基苯乙基)丙醯胺酸,p . 137 - 139 °C ° · 肀4(210Χ 297Υ^) —24 — 219928 A6 B6 五、發明說明(23) (請先聞讀背面之?±意事«再填3?本页) 一 (d)網似·實例1⑻之方法,352毫克的N—〔 3 —(第三 .,丁氧羰基)一 N_〔(對位一氰基苯乙基胺甲醯基)乙 醯'〕·一 L _丙胺醯〕一3 -苯基—L -丙胺酸第三,丁基 酯,MS : 607 ( M+H ) +,可由300毫克的前躯體與5〇7毫 克的H-Asp(0-tBu)-Phe-0-tBu 偶合,再於矽膠上以乙酸 乙酯層析而得。 . ⑹類似實例1⑹,⑻及(f)之方法,利用380毫克的(d)產 物,可在二異丙醚結晶'化作用後,獲得152毫克的N —〔 N—〔(對位一甲脒基苯乙基胺甲醢基)乙醯〕一3—( -第三,丁氧羰基)一L 一丙胺醯基〕一 3 —苯基_L:·-丙 胺酸第三,丁基酯氫碘酸塩,m.p. 91 — 分解作 用)。 實例6 - 119毫克的N—〔 N — ( 4 —(對位一甲脒基苄醯胺基 )丁醯〕一 L — α—天冬胺醯基〕一 L 一游|胺酸之三氟醋 酸塩,m.p. 174 °C (分解作用),可以類似實例1之方 法,得自200毫克的N —〔N —〔 4一(對位一甲脒基ΐ 醯胺基)丁醣〕一 3 —(第三,丁氧羰基.)一 L —丙胺睡 基〕一L 一方'|胺酸第三'.丁基酯氫碘酸塩,及自乙醇/二 乙醚中再結晶化作用後。 經濟部中喪搞準扃印¾ 起姶物質之製備如下: ⑻依實例1⑻所述,偶合783毫克的Ζ — 4 _胺基丁酸 及 1 克的 H-Asp(0-tBu)-VaL_0-tBu (得自 Z-Asp(0-tBu) -OH及H-VaL.-O- tBu之縮合作用,再行解作用),自矽 -25 - f 4(210X 297^'^) A6 B6 _21992b 五、發明説明(24 ) {請先聞讀背面之•注意事頊再填寫本页) 辱±以乙酸乙酯層析及利用己烷結晶化後,可得i . 17克 的N —〔 N —〔 4 一(丨~(平氧基)胺甲醯基〕丁釀胺基〕一 3二C第三,一丁氧羰基)一L —丙胺醯〕一 L-—杉|胺酸第 三,丁基酷 ’ m. p · 64 — 65 °C。 (b)以類似1 (b)之方法,氫解1. 1克的前軀Μ,可得1克 的Ν —〔 Ν — ( 4 —胺基丁齲基)一3' —(第三,丁氧羰 基)一L —丙胺醯〕一 L —忽|胺酸第三,丁基酯,m.p. 99 一 100。。。 ' (C)將859毫克(b)產物,於0 X:下2小時後加至324毫克 甲 -4 —氰基苯甲酸,352毫克2 —氯一 4,6-二&氧基一 :1,3 ,5 _三^及0.24毫升N —甲基嗎福味f於10毫升二甲替甲 醣胺之溶液中。令混合物加熱至室溫,經實例1⑹般處理 ,及於矽膠上以乙酸乙酯層析後,可得772毫克的N — & N —〔 4 一(對位一氰基苄醣胺基)丁醣〕一 3—(第三 ,丁氧羰基)一 L 一丙胺醯基〕一L 一胺酸第三,丁基 酯,MS : 5i9 ( Μ十Η ) + 。 經濟部中央搮準局印裝 (d)若760毫克(c)產物,接受如實例1 (d)、⑼及(f)所述之 相同反應序列,經以二異丙醚結晶化作用.後,可得444毫 克的N —〔 N —〔 4 一〈對位一甲脒基苄醯胺基)丁醯基 一 3_ (第三,丁氧羰基)_L_丙胺醯一L 一拉|胺酸第 三,丁基酯氫碘酸塩’,m · ρ · 105 — 107 ·(:(分解)。 實例7 1.09 克的外消旋一 N - 1 -〔〔〔對位~㈧一(苄氧 羰基)曱脒棊〕苄醯基〕一3 —六氫吡啶基〕羰基〕一卢 甲4(210X 297公沒) —26 — A6 B6 五、發明說明(25 ) . - — -. * 一丙暌酸;酯,及〇.25克的Pd/c,於氫氣下在20毫升醋 酸中攢拌。濾出晶體,濾液蒸發。殘留物中加入水再蒸發 溶液。沈澱物懸浮於甲醇中,以氨水調至PH 8再攢拌, 之後眞空過濾並以甲醇洗滌及乾燥,可得530臺克的外消 旋一 N —〔〔 1 —(對位一甲脒基苄醯基)二3 —六氫吡 啶基〕羰基〕一Θ —丙胺酸,呈水合物型式(2:1 ), m. p. >265 °C » MS : 347 ( 96 , M+H ) 〇 起始物質製備如下 ⑻外消旋一Ν—(第三,丁氧羰基)六氫吡啶基一3— -竣酸(Can, J. Physiol. Pharmacol. 57,1979, 763-)於 THF,以氯二甲氧基三p毒及N —甲基嗎福活化,之後與 /3 —丙胺酸苄酯對位一甲苯磺酸塩(J. 〇rg. Chem· 17, 1952, 1564 ) 及N-甲基嗎福<偶合,可生成外消旋一 Ν —〔〔 1一(第三,丁氧羰基)一 3 —六氫吡啶基〕羰 基〕一 /3 —丙胺酸苄酯,m · ρ . 57 — 59*C。 (b)以三氟醋酸解,離,可自其中獲得外消旋一(3 —六氫 * 吡啶基羰基)一#一丙胺酸苄酯之三氟醋酸塩。 ⑹於二氯甲烷/碳酸氫鈉水溶液中,以·對位一甲脒苄醯 氯反應,再於碳酸鈉.存在/下與氯甲酸苄酯反應,可生成外 消旋一 N—1 —〔〔〔對位一〔N—(苄氧羰基)甲脒基 〕苄酿基〕一 3 —六氫批唆基〕羰基〕一 /3 —丙胺酸苄酯 ,MS : 571 ( 10,M+H )。 實例8 512毫克的N —〔 4 —〔對位一〔N —(平氧擬基)甲 ......................................................it..............................ίτ..............................*!. {請先閱讀背面之.注意事邛再填寫本页) · 中 4(210X2971、发) -27 - A6 B6 219928 五、發明説明(26) 脒棊〕苄镰胺基〕丁醯〕一卢一丙胺酸苄酯及17〇毫克的 Pd/c於10毫升醋酸,在氫氣下搅拌。濾出催化劑,再將 璩液·蒸發。殘-留物溶於水且溶液蒸發。殘留物懸浮於水, 以氨水調至PH 7,眞空過璩,以水洗後乾燥。可得239毫 克的N —〔 4-(對位一甲脒基爷醣胺基)丁醣〕一 |9一 丙胺酸,m.p. > 250。(:,MS : 321 ( 12,M + H.)。 起始物可如下製備: ⑻4 -(第三,丁氧‘羰基胺基)丁酸於THF,以氯二甲 氧基三及N —甲基嗎福β坏活化,再於N —甲基嗎福外f存 _在下與卢一丙胺酸苄酯對位一甲苯磺酸塩反應,可得「N — 〔4一( 1_第三,丁氧基甲醯胺基)丁醯〕一 Θ —丙胺 酸苄酯,m.p. 54 - 55 °C。 (b) 所得的溶於三辱醋酸,可得N_ ( 4 —胺基丁醣)〜 芦一丙胺酸苄酯之三氟醋酸塩。 (c) 後者於二氯甲烷/水/碳酸氫鈉中與對位—甲脒基苄 醯氯反應,再於碳.酸鈉存在下與氯甲酸苄酯反應,可得N 一〔4 —〔對位一〔N—(苄氧羰基)甲脒基〕苄醢胺基 〕丁醯〕一 /3 —丙胺酸苄酯,m.p. 173 — 183 ’C。 實例9 經濟部中央拢準局印裝 類似實例8,N —〔N —(對位一甲月米基苄醯基)一 /3 -丙胺醯基〕一卢一丙胺酸,m. p - > 250 °C,M S : 307 (6,Μ + Η)可呈水合物(2:1 )型式得自Ν —〔 Ν_〔 對位一〔Ν —(苄氧羰基)甲脒基〕苄醯〕一 丙胺醯 基〕一iS —丙胺酸苄酯。 甲4(210X 297公发) —28 — A6 B6 219928 五、發明說明(27) _ . 起雉物質可製備如下: {請先聞讀背面之.注意事ifi再填寫本頁) ⑻N—(第三,丁氧羰基)一卢一丙胺酸及卢一丙胺酸 苄醒·,類似以·上貢例地偶合,生成N —〔N—-(第三,丁 氧羰基)一卢一丙胺醸基〕一 i3 —丙胺酸苄酯,m.p. 84 - 85 °C ° (b) ( /9 —丙胺醢基)一/3 —丙胺酸苄酯得自於三氟醋醴 中〇 (c) 此可與對位一甲睐·基苄醯氯及接下來與氯甲酸苄酯反 應,以生成N —〔 N —〔對位一〔N —(苄氧羰基)甲脒 -基〕苄醯〕一卢一丙胺醯基〕一卢一丙胺酸予酯,m.:-p . 165 — 166 C ° 實例10 類似實例8,N_〔(D L _) — N —(對位一甲脒基苄醣 )一 3—苯基一卢一丙胺醯基〕一 0 —丙胺酸,以水合物 型式(3i l)m.p. > 250 °C,MS : 38 3 ( 62, Μ + H) ,得自Ν —〔(DL) — Ν—〔對位一〔Ν —(苄氧羰基) 甲脒基〕苄醯〕一 3 一苯基—丙胺醯基〕—Θ 一丙胺 酸苄酯。 . 起始物質可如下製備 M濟部中央》準局印裝 ⑻PL — N—(第三,丁氧幾基)一3 —苯基一 /3 —丙-胺 酸及Θ —丙胺酸苄酯‘,類似上實例般偶合,可得Ν —〔 (DL)— Ν —(第三,丁氧羰基)一 3—苯基一卢一丙胺 醯基〕一卢—丙胺酸苄酯,m.P. 143 — 144°C。 (b)〔(DL).— 3 —苯基一/3 —丙胺醯基〕一/3 —丙胺酸 甲 4(210X 297公尨) 一29 — A6 B6 219928 五、發明說明(28 ) _ . 苄曄之三東醋酸塩,可得自三氟醋酸中。 請先閲讀背面之•注意事顶再填"本页) ⑹此與對位一甲脒基苄醯氯反應,再與氯甲酸苄醋反應 ,以-生成N —-〔(DL)-N -〔對位一〔N —-(苄氧羰基 )甲脒基〕苄醯基〕一 3 —苯基一 /9 一丙胺醯基一卢一丙 胺酸苄酯,πι·ρ· 187 — 189 X:。 實例11 443毫克的Ν-〔 3_〔(苄氧基)羰基〕一Ν-〔 5 一〔對位一〔Ν —〔 Γ苄氧基)羰基〕甲脒基〕苄醯胺基 〕戊醯〕一 L 一丙胺醯基〕一 3—苯基一 L 一丙胺酸苄酯 及111毫克的Pd/c 於9毫升醋酸中,在氫_氣下攪拌:'3 Κ2 小時。溶液過濾及蒸發,殘留物溶於水中,且溶液再次蒸 發。殘留物於水中搅拌,眞空過谳再乾燥。可得246毫克 的Ν-〔Ν —〔 5—(對位τ·甲脒基苄醯胺基)戊醣基> —L 一《 —天冬胺醯基〕一3 —苯基一L -丙胺酸,m.p. 241°C,呈水合物型式(1:2 )。 起始的酯,m· ρ · 169 — 171 X:可如下製備: ⑻N —(第三,丁氧羰基)一L —天冬胺酸4 一苄基酯 與3 —苯基一 L 一丙胺酸苄酯偶合,生成.N —〔 3 —〔( 苄氧基)羰基〕一N —-(第三,丁氧羰基)一L 一丙胺酿 〕一3 —苯基一 L —丙胺酸平酷,m.p. 93 — 94 *C。 烴濟部中央棣準局印浆 (b)此以三氟醋酸去保護,再與5 — ( 1 —第三,丁氧基 丙醯胺基)戊酸偶合,生成N —〔 3 —〔(苄氧基)羰基 〕~-N —〔 5— ( 1—第三,丁氧基甲酿胺.基)戊酿〕一 L —丙胺醯棊〕一3 —苯基一 L —丙胺酸苄酯,m.p. 甲 4 (210X297 公发) —30 — 219928_ Be 五、發明说明(29) 119.5 - 120.5 *C ° (c)後者於三氟醋酸中除去第三,丁.氧羰基保護基,再轉 化成-起始物質· *於二氯甲烷/水/碳酸氫鈉中-,利用對位 一甲脒基苄醯氯再與氯甲酸苄酯反應。 實例12 類似實例11,NW -〔〔( S )—(勤位一甲脒基苄醯胺 基)伸乙基〕二羰基〕二一卢-丙胺酸,m.p. > 250 °C ,得自叱>1,一〔〔(^)-〔對位一〔1^-〔(苄氧基) 羰基〕甲脒基〕苄醍胺基〕伸乙基〕二羰基〕一二一卢一 -丙胺酸二苄基二酯,經本蒸發及以甲醇攪掸.。 . 起始的酯,m.p. 171 — 172 X:,如下獲得: ⑻N—(第三,丁氧羰基)一 L —天冬胺酸與2當量的 芦一丙胺酸苄酯偶僉,生成N,Nf —〔〔(S) — ( 1 —第 三,丁氧基甲醯胺基)伸乙基〕二羰基〕二一 |9一丙胺酸 二苄基酯,m.p. 109 — 110°C。 (b)於以三氟醋酸,解離第三,丁氧羰基後,產物於二氯甲 烷/碳酸氫鈉水溶液中與對位一甲脒基苄醯氯反應,再與 氣甲酸苄酯反.應,以生成起始的酯。 實例13 ,· 烛濟部中衣《率扃印鉍 (請先閑讀计面之-注意事项再填寫本頁) 類似實例11,2_N^(對位一甲脒基苄醯基)4— N 一(2 —羧乙基)一L 一精胺酸,m.p. 21〇°C (分解) 得自N —〔(S) — N —〔對位~〔n —〔(苄氧基)羰基 〕甲脒基〕苄醢基〕一 3 —〔(苄氧基)羰基〕—卢―丙 胺醯基〕一/3. —丙胺酸苄酯。 ' 中4(210X 297公发) -31 - 219928_ Be _ 五、發明説明(30 ) _起始的酯如下獲得: ⑻N—(第三,丁氧羰基)一 L —天冬胺酸1 一苄基酯 與芦·一丙胺酸·平酯偶合,生成3 —〔〔( 2 (苄氧基 )羰基〕乙基〕胺甲醯基〕一N-(第三,丁氧叛基)一 L -丙胺酸苄酯,m. p ? 77 — 78 °C。 .— (b)終於三氟醋酸中解離第三,丁氧羰基保護基後,產物 於二氯甲烷/水/碳酸氫鈉中與對位一甲脒基苄酿氯偶合 ,再與氯甲酸苄酯反應以生成起始的酯,m.p。 122 — 12 3 .C。 實例14 … 類似實例8,N —〔 5—(對位一甲脒基苄醣胺基)戊 醯〕一卢一丙胺酸,m.p. > 280eC,.得自 N —〔5—〔 對位一〔N—〔(苄氧基)羰基〕甲脒基〕苄醣胺基〕戊 酿J- /3 —丙胺酸苄酯,。 起始的酯可如下製備: • *. ⑻5 —( 1 一第.三,丁氧基甲醣胺基)戊酸與卢一丙胺 酸苄酯偶合,生成N —〔 5 —〔(第三,丁氧基甲醯胺基 )戊醯〕一一丙胺酸苄酯,m· p · 69 — .7(TC。 (b) N — ( 5 —胺基戊醯..)一Θ —丙胺酸苄酯之三氟醋酸 塩,得自三氟醋酸中。· 經濟部中央橾準局印裝 {請先聞讀背面之注意事項再填寫本頁) (c) 此於二氯甲烷/水中,及碳酸氫鈉存在下與對位一甲 脒基苄醯氯反應,再與氯甲酸苄酯反應,生成起始的酯, m.p. 161 - 1 6 1.5 *C 0 實例15 甲 4(210X 297W发) 一32 — A6 B6 τ甲脒基一 219928 五、發明說明(31) 704 毫-克的外消旋一N —〔〔 1一〔 3 -〇-( E / Z )) — Ν,ν—雙一(第三,苄酯,及176毫克的Pd/c於 14'.-1毫升甲-酸中,在氫氣下攪掸18小時。爐-出催化劑, 以1:1甲酸/水洗漉。濾液蒸發,殘留物溶於水,溶液則 再次蒸發。殘留物於矽.膠上利用乙醇/甲醇層析。可得 254毫克的外消旋一 N —〔〔 1 -〔 3 4 一六氫吡啶基)丙醢〕一 3 —六氫吡啶基〕羰基〕一卢 -丙胺酸,MS : 382(ί00, M+H )。 起始的酯可如下製備: ⑻4 一六氫吡啶基丙酸與Ν,Ν,一雙(第三,丁氧錁基 )—S —甲基买硫脲,於第三,丁醇及2 Ν氫氧化鈉之溶 液中反應,可得3 —〔 1 一〔(Ε/Ζ) — Ν,Ν,一雙(第 三,丁氧羰基)甲脒基〕一4一六氫吡啶基〕丙酸。 ^ . . (b)止於外消旋一 Ν —( 3 —六基吡啶基羰基)一0 —丙 胺酸苄酯偶合,可得起始的酯,MS : 672 ( 12, M + Η )。 * 實例16 {請先聞讀背面之注意事邛再瑱寫本页) 115 毫克的 Ν —〔〔(S)— 1 —〔對位一〔Ν —〔(苄 氧基)粮基〕一甲脉基〕午酿基〕一 2 —.批略瞭基〕乙睡 /3 —丙胺酸及 姐 濟 中 央 接 準 Mi 印 基〕一 醋酸中攢挣4小時。 再次蒸發並於 水中 Ν 切毫克的Pd/c,於氫氣下及2.5毫升 催化劑濾出,溶液蒸發。殘留物溶於 矽膠上利用甲醇層析。可得46毫盍的 〔〔(S) — 1 —(對位一甲眯基苄醯基)—2 一吡咯 乙醯基〕一卢一丙胺酸,m.p. >250。0。 啶基〕 起始的酯可如下製備: 甲 4(210X 297H*) -33 - A6 B6 219928 五、發明説明(32 ) · • — · ' {請先W讀背面之"意事邛再填駕本百) (a) (S) — 1 一〔(苄氧基)羰基〕一 2 一吡咯啶醋酸與 卢一丙胺酸第三,丁基酯偶合,生成N 一〔〔(S)_ 1 一 〔 '(.干氧基)-.叛基〕一2 —卩比塔陡基〕乙酷基-〕一Θ —丙 胺酸第三,丁基酯,MS: 391( 69,M + H ) ° (b) N—〔( 2 —批略.胺基)乙醯〕—卢,丙胺酸第三, 丁基酯之醋酸塩由此中於醋酸氫化作用而得。. (c) 此於二氣甲焼/水中’及碳酸氣鈉存在下與對位—甲 脒基苄i||_氯反應,再負氯甲酸苄酯反應,可得N_〔〔( 一〔對位一 〔N —〔(苄氧基)羰基〕甲脒基 -〕苄醯基〕一 2 —吡咯啶基〕乙醯〕一卢一 _丙胺酸第三, 丁 基酯,m. p。 127 — 128 X:。 (d) 起始的酯,MS : 481 ( 100,M+H ),得自此中甲酸 中。 〆 實例17 300毫克的苄基一(S) — 3 —〔〔 N -〔對位一〔N- (第三,丁氧羰基,)甲脒基〕苄醯基〕一 P —丙胺醯基〕 • 胺基〕一3—〔(對位一甲氧基苯乙基)胺甲醯基〕丙酸 酯,及75毫克的Pd/c,於6毫升甲酸中,·在氫氣下攪拌 4 Η小時。濾出催化劑、,攄液蒸發,殘留物中加入水,溶 液再次蒸發。結晶物質懸浮於水中,以氨水攪拌調至ΡΗ 8 ,再眞空過濾。可得Ϊ51毫克的(S)— 3 —〔〔Ν —(對 位一甲脒基苄醯基)一 jS —丙胺醸〕胺基一3 —〔(對位 _甲氧基苯乙基)胺甲醯基〕丙酸,呈水合物(1:1 ), m. p . 217 °C. ° f 4(210X 297^'^) —34 _ A6 B6 219928 五、發明說明(33) .. - .— _起维的褶可如下製備: ⑻/5 —丙胺酸苄酯於二氯甲烷/碳酸氫鈉水溶液中與對 位二·甲脒基苄葡氯反應,再與二碳酸二第三,·丁基酯及碳 酸鈉反應,生成N —〔對位一〔N —(第三,丁氧羰基) 丙脒基〕苄醢〕一卢一丙胺酸苄酯,m.p·. 127 — 128 Ϊ。 (b)N -(第三,丁氧羰基)天冬胺酸4 —苄酯與2 —( 4 一甲氧基苯基)乙胺偶合,生成〔(S) — 2 —〔 C苄氧 基)羰基〕一1一〔 Γ對位一甲氧基苯乙基)胺甲醯基〕 乙基〕胺基甲酸第三,丁基酯,m.p. 103 — 104 。 ⑹由此於三氟醏酸中,可得3 —〔(對位一甲氧基苯乙 基)胺甲醯基〕一 丙胺酸苄酯之三氟醋酸塩。
⑻後者與(b)之產物偶合,生成起始的酯,m· ρ . 150 eC (分解)。 身 實例18 類似實例8,N —〔 N —〔 N —(對位一甲脒基苄醯基 ' ·. )—/5 —丙胺醯基〕一 L — α —天冬胺醯〕一 L_.5胺酸 異丙基酯呈水合物型式獲得(1:1.3) ,m.p. 234 °C( 分解),得自N —〔3 —〔(苄氧羰基〕_—N —〔N-〔 對位一〔N -〔(苄氧基.)羰基〕甲脒基〕苄醯〕一 /3-丙胺醯基〕一L 一丙胺酺基〕一L 一百胺酸異丙基酯。 起始的酯以下列方式獲得: ⑻N —(第三,丁氧羰基)一L 一百胺酸轉化成N-( 第三,丁基羰基)一 L —百胺酸異丙酯,〇〕D = — 33° .* 每 (MeOH,c =.0.5 ),利用二環己基碳化二亞胺,對位一甲 {請先閱讀背面之•注意事邛再琪荈本页) .装· .打· • af. 甲 4(210X 297 公沒) —35 — Λ A 6 _219928_ Β6 _ 五、發明説明(34 ) 苯磺酸及異,丙醇於吡啶。 (b)L —百胺酸異丙基酯之三氟醋酸塩,得自其中於三氟 醋酸…. - ⑹此與N-(第三,丁氧羰基)一L 一天冬胺酸4 —苄 基酸偶合,生成N —〔3—〔(千氧基)羰基〕一N—( 第三,丁氧羰基)一 L 一丙胺醯基〕一L 一百胺酸異丙酯 ,MS : 479 ( 25, M + Η )。 (d) 經解離第三,丁氯羰基保護基後,再與Ν —(第三, 丁氧羰基)一0 —丙胺酸偶合,可得N —〔 3 —〔(苄氧 -基)羰基〕一N -〔 N —(第三,丁氧羰基)一卢一:丙胺 醯基〕一L —丙胺醯基〕一L —百胺酸異丙、酯,m.p. 103 — 104 *C ° (e) 此在三氟醋酸中除去第三,丁氧羰基保護基,再於2 氯甲烷/水/ 碳酸氫鈉中,以對位一甲脒基苄醯氣及接下 πί— 來的氯甲酸苄酯反應,轉化成起始的酯,πκρ ·λ177 °C。 實例19 類似實例8,可得N —〔〔(R)— 1 一(對位一甲眯基 苄醯基)一 3 —吡咯啶基〕羰基〕一卢一.丙胺酸,水合狀 C 4: 3 ) » m.p. > 250.-C » C«]d =-4.13 ( IN HCI , *- . c = 0.46 % ),得自 〔〔(R) - 1 —〔對位一〔N- 班濟部中衣沭準历印$1· {請先閏讀背面之.注意事Jfi再填3?本页) 〔(苄氧基)羰基〕申脒基〕苄醏〕一3—吡咯啶基〕羰 基〕丙胺酸苄酯。 起始的酯如下製備: ,⑻(R)_l 一〔(R) — Λ —甲基苄基〕一3 —吡咯啶 f 4(210X 291^ fi) —36 — A6 B6 219928 五、發明説明(35 請 先 聞 讀 背 I 事 再 填 寫 本 π 基甲醇,-二碳酸二第三,丁基酯及Pd/c於乙醇,在氫氣 下攪拌20小時,可得(R) — 3 —(羥甲基)一1 一吡咯啶 基竣·酸第三,--丁基酯,m. ρ· 35°(:,〔《〕1>=-+19.5。(甲 醇,c = 1.0 )。 (b)由此,利用二鉻酸吡啶於DMF,可得(R ) — 1 一(第 三,丁氧羰基)一 3 —吡咯啶基羧酸,m. p . 135 — 138 °C > C « ] 〇 =-15 0 ( MeOH , c = 1.0 ) ° ⑹此與沒一丙胺醆苄_醋偶合,生成N-〔〔(尺)一1-(第三,丁氧羰基)一 3 —吡咯啶基〕羰基〕一 Θ —丙胺 酸苄酯,111.口. 83 - 84。(:,〇〕1>=—3.4。(]^011,:- c = 1.0 ) 0 ⑹N —〔〔(R) — 3 —吡咯啶基〕羰基〕一θ —丙胺酸 苄酯之三氟醋酸塩,由此得自三氟醋酸。 / ⑹此於二氯甲烷/水/碳酸氫鈉中,與對位一甲脒基苄 疏氯及接下來的氯甲酸苄酯反應,生成起始的酯,〔《〕〇 = +2.2。,( MeOH , c = 0.5 ) ° - 實例20 班洚部中夹谇举历印长 類似實例16,N —〔 N —(對位一甲脒基苄醸基)一 2 一甲基一0 —丙胺醯.基0.-L —天冬醯胺(2:1差向異構 賸),m.p. 280·0 得自(S)— 3 —〔〔 D/L—N —〔對 位〔N —〔(苄氧'基)羰基〕甲脒基〕苄醯〕一 2 —甲基 一 /3 —丙胺醯基〕胺基〕琥珀醯胺酸苄酯。 起始的酯如下製備: ⑻(S) — 3. —( 1 一第三,丁氧基甲醯胺基)琥珀醯胺 甲4(210Χ 297乂发) -37 - A6 B6 ^19928 五、發明説明(36) _苄基酯,利用三氟醋酸去保護基,再與DL — N —(第三 ,丁氧羰基)一 2 —甲基一 /3 —丙胺酸偶合,可得〔(R S )二2 —〔〔_( S ) —4一〔(苄氧基)羰基〕一 b一胺甲酿基 乙基〕胺甲酿基〕丙基〕胺基甲酸,第三,丁基酯,m· p. 135 - 136 °C ° (b)經於三氟醋酸中解離第三,丁氧羰基保護基後,產物 於二氯甲烷/水/碳酸氫鈉中與對位一甲脒基苄醯氯偶合 ,最後再與氯甲酸苄塞·酯反應,以生成起始的酯(2:1差 向異構物),m.p. 178.5 — 179.5 X:。 -實例21 … 548毫克的N_〔 N —〔對位一〔N —(第三,丁氧羰 基)甲脒基〕苯基〕乙醯基〕一 > 一丙胺醯基〕一|9 一丙 胺酸苄基酯令其置於11毫升甲酸中18小時。於加入137毫 克的Pd/C後,混合物在氫氣下搅拌4小時。濾去催化劑 ,且濾液蒸發。殘留物溶於水,溶液再次蒸發。殘留物懸 ·> 浮於水中,並以氨,水調至PH 8,之後眞空過濾再乾燥。可 得290毫克的N-〔N-〔(對位一甲脒基苯基)乙醯〕 —泠一丙胺酿〕一々一丙胺酸,呈水合物.形式(1 : 1 ), m. p . 286 °C (分解),。. 起始物質,m. p . 262 ·0 (分解)藉著N-(卢一丙胺 班濟部中央详準A印$1 酿基)一 /3 —丙胺酸苄基酯於DMF /三乙胺中與對位一甲 脒基苯基乙醯氯反應,再與二碳酸二第三,丁基酯反應。 實例22 535毫克岡外消旋一N-〔〔 1-〔如位一〔N-(第 肀 4 (210X297 X 犮) -38 - A6 B6
21992R 五、發明說明(37 ) {請先閱讀背面之_注意事-^再填寫本页) Ξ , 丁氧羰基)甲脒基〕苯基乙酿〕一 3 —六氫吡啶基〕 /9 一丙胺酸苄基酯,令靜置於11毫升甲酸中19小時。溶 劑蒸·發,殘留·物以水蒸發,再自乙膪中再結晶。可得340 毫克的外消旋一N —〔〔〔 1 —(對位一甲脒基苯基)乙 醯〕一 3 —六氫吡啶基.〕羰基〕一 ^ 一丙胺酸苄基酯甲酸 塩(1 : 1 ) ,m. p · 97 - 98 °C。 .. 起始的酯,MS: 551(9, M+Η)由4消旋一 Ν-〔( 3 —六氫吡啶基)羰甚乃一〆一丙胺酸苄基酯於DMF /三 乙胺中,與對位一甲脒基苯基乙醯氯偶合,再與二碳酸二 -第三,丁基酯反應而得。 . 〜:· 實m 23 535毫克的外消旋一N —〔〔1一〔對位一〔N —(第 三,丁氧羰基)一甲脒基〕苯基乙醢基〕一 3 —六氫吡啶 基〕羰基〕一 —丙胺酸苄基酯,令靜置於11毫升甲酸中 19小時,混合物以134毫克Pd/C處理,並在氫氣下攪拌 * 4小時。溶液過濾.及蒸發,殘留物溶於水中,溶液再次蒸 發。產物於乙膪中攢掸,眞空過璩再乾燥。可得272毫克 的外消旋一 N —〔〔 1 ~〔(對位一甲脒.基苯基)乙醣〕 —3 —六氫吡啶基〕,療基.〕一 一丙胺酸,MS:361(41, M+H )。 嫌 ;» 部 中 導 Mi 印 實例24 ‘ 1127 毫克的N-〔3 -〔(苄氧基)羰基〕一N —〔 N-〔3 —〔1-〔(E 或 Z)-N,N'雙(第三,丁 氧羰基)甲眯基〕一 4 一六氫吡啶基醯〕一0 —丙胺 f 4(210X297 公廣) jy — A6 B6 219928 五、發明說明(38) 鷗基〕一 L 一丙胺醯基〕一 3 —苯基一L 一丙胺酸苄基酯 ,令靜置於22.5毫升甲酸中21小時,於加入282毫克的 Pd/C後,混合物在氫氣下攢掸5小時。溶液-過濾及蒸發 ,殘留物溶於水,溶液再次蒸發。殘留物於水中攪拌,眞 空過濾再乾燥。可得543毫克的N_〔 N-t: N —〔 3 — (1 一甲脒塞一 4 一六氫吡啶基)丙醯基〕一厂一丙胺醯 基〕一 L— α —天冬胺醢基〕一3 —苯基一L—丙胺酸, m. ρ ·' 246 °C (分解 乂·。 起始的酯如下製備: ⑻N —(第三,丁氧羰基)一/3 —丙胺酸與N —〔':·3 — 〔(平氧基)幾基〕一L一丙胺酿基〕一3—苯基一L— 丙胺酸苄基酯偶合,可得Ν—〔3—〔(苄氧基)羰基〕 一 Ν —〔 Ν —(第三,丁氧羰基)一/9一丙胺醯基〕一fc 一丙胺酿基〕一3 —苯基一L 一丙胺酸午基醒》m.p·.124 -125 *C ° (b)經解離第三,.丁氧羰基保護基後,產物與3 —〔 1 一 - 〔N,NT —雙一(第三,丁氧羰基)甲脒基〕一 4 一六氫 吡啶基〕丙酸.偶合,生成起始的酯,1 : 1 ·乙酸乙酯溶劑化 物,m.p. 100°C (.分解..)。 實例25 · 1.3克的3 —〔(苄氧基)羰基〕一 N —〔5 —〔對位 —〔N-〔(苄氧基)羰基〕甲脒基〕苯醯胺基〕戊醯〕 -L —丙胺酸異丁基酯,及325毫克的Pd/_C於25毫升醋 酸中,在氫氣下攪拌534小時。溶液過濾及蒸發,殘留物 甲 4(21〇X 297W发) (請先閃讀背面之 k意事頊再填寫本页) •装· 蜮濟部中喪搮準局印裝 —40 — A6 B6 219928 五、發明説明(39 ) {請先聞讀背面之_注意事邛再填寫本頁) 繼以水·、甲醇及乙醇蒸發。產物以氨水於乙膪中,至 ΡΗ 8,攪掸再眞空過濾。可得596毫克的Ν—〔 5 —(對 位一-甲脒基苄-酿胺基)戊醯〕一 L 一《 —天冬.胺酸異丁基 酯,呈水合物(1 : 1 ) ,m. ρ . 162 — 166 °C。 起始的酯,m. p · 127.5 — 129.5 t:,可如下製備: ⑻N —(第三,丁氧羰基)一 L 一《—天冬胺酸苄基酯 轉化成N —(第三,丁氧羰基)_3 — ‘〔(苄氧甲)羰基 〕一L -丙胺酸異丁基·醒,MS : 323 ( 8,M - C4H8),利 用二環己基碳化二亞胺,對位一甲苯磺酸,及異丁基醇於 -吡啶。 ⑼經於三氟醋酸中解離第三,丁氧羰基後,產物與5 — (1_第三,丁氧基甲醯胺基)戊酸偶合,生成3 —〔( 苄氧基)羰基〕一N —〔5— ( 1—第三,丁氧基甲醯胺 基)戊醯〕一L 一丙胺酸異丁基酯,m.p. 64 — 66 eC。, ⑹此利用三氟醋酸去保護基,再於二氯甲烷/水/碳酸 氫鈉中與對位一甲肤基苄醯氯反應,之後再與氯甲酸苄酯 反應,以生成起始的酯。 實例26 蜮濟部中衣«準扃印鉍 562 毫克的(S)-卢 r.〔 〔DL-N —〔對位一〔N —〔 (苄氧基)羰基〕甲眯基〕苄酿〕一 3 —甲基一 Θ —丙胺 酿基〕胺基〕一Γ _氧基一 1 一批略唆基丁酸午基酷,及 140毫克的Pd/C於11毫升的醋酸中,在氫氣下攪掸2小 時。濾過的溶液蒸發,殘留物相繼以水、甲醇及乙醇蒸發 。殘留物於乙醇中以氨水仔細調至PH '8'攪拌再眞空過據 中 4 (210X297 公发) —41 — A6 B6 219928 五、發明說明(40) {請先聞讀背面之注意事4再填寫本页) 。可得289毫克的(S)-i3 -〔〔DL-N-(對位一甲脒 基午酿)一3 —甲基一 /3 —丙胺醯基〕胺基〕一;· 一氧基 —1-一批塔唆-基丁酸,呈水合物(2:3 ) m.p_. 222^"^。 起始的酯可以下列方式製備: ⑻(S ) — P —( 1 一第三,丁氧基甲醯胺基)一 r —氧 基一1 一吡咯啶基丁酸苄酯,利用三氟ΪΙ酸去保護,再與 (RS) — 3— ( 1_第三,丁氧基甲醯基)丁酸偶合, 可得(S) — /9 —〔(R:S) — 3— ( 1 —第三,丁氧基甲醯 胺基)一丁醯胺基〕一 Γ 一氧基一吡咯啶基丁酸苄基酯, m. p . 104 - 105 °C 。 ... - , (b)由此,起始的酯,MS : 642 ( 100, M+H ),其獲得是 於三氟醋酸中解離第三,丁氧羰基,與對位一甲脒基苄醯 氯反應,再於二氯甲烷/水/碳酸氫鈉中與氯甲酸苄酯反 應。 實例27 類似實例8,自DL—N—〔N —〔對位一〔N —〔(苄 氧基)羰基〕甲脒基〕辛醯基〕一卢一丙胺醯基〕一 3 — 甲基一 /9 一丙胺酸苄基酯,可得DL—N~〔N —(對位一 甲脒基苄醯基)一 /5.—丙胺醯基〕一3 —甲基一/3 —丙胺 酸,呈水合物(3:1 ) ,m.p. 291t:(分解)。 經濟部中我揲隼扃印鉍 起始的酯,m.p. 179 — 180°C,可如下製備: ⑻N —(第三,丁氧羰基)一# 一丙胺酸與DL — 3 —胺 基丁酸苄酯偶合,可生成DL — N_〔 N —(第三,丁氧搜 基)一 P —丙胺醯基〕一3 —甲基一Θ二丙胺酸苄酯, f 4(210X 297 公发) 42 219928 A6 B6 五、發明説明(41) m. p . - 70 — 72 1 2C ° (b)DL—N—(卢一丙胺酿基)~~ 3 —甲基一(S —丙胺酸 苄醋_,可由此-利用三氟醋酸獲得。 ⑹此於二氯甲烷/水/碳酸氫納中,與對位一甲肤基平 醯氯反應,再與氣甲酸苄酯反應,可得起始的酯。 經洚部中衣煤泽局印鉍 {請先閲对背面之注意事项再填寫本頁) 43 — 1 實例28 . 類似實例8,N —〔N —〔 N~ (對反一甲脒基苄醯基 )—丙胺醯基〕2-L —《—天冬胺醯基〕一 L —絲胺 酸乙酯可以水合物(2:7 )獲得,m. p · 201 - 203 °C » .得自N —〔 3—〔(苄氧基)羰基〕一 N-〔N —〔.對位 一〔N —〔(苄氧基)羰基〕甲脒基〕苄醯基〕一$ —丙 胺醢基〕一L 一絲胺酸乙酯。 起始的酯,m· p . 177 — i.79 °C,可如下製備: 一 ⑻N —(第三,丁氧羰基)一L 一《—天冬胺酸苄棊酯 與L —絲胺酸乙酯偶合,生成N —〔 3 —〔(苄氧基)搜 2 ·. 基〕一N—(第三,丁氧羰基)一L一丙胺醯基〕 一 L 一絲胺酸乙酯,m.p. % — 97X:。 (b) 解離第三,丁氧羰基後,產物與N-.(第三,丁氧羰 基)一 P —丙胺酸偶.合.,生成N —〔 3_〔(苄氧基)搜 基5 — N_〔 N-(第三,丁氧羰基)一卢一丙胺醯基〕 —L -丙胺醯基〕’一L 一絲胺酸乙酯,m.p. 132-134 •C〇 丨 (c) 此於三氟醋酸中去保護,產物再於二氯甲烷/水/碳 酸氫鈉中與對位一甲脉基午酿氯反應’蠢後與氯甲酸平醋 甲 4(210X 297 0:;%2;. 219928 A6 B6 五、發明說明(42 ) 适摩,生-成起始的酷。 實例29 類·似實例8 - , N -〔 D L - N —(對位一甲脒基苄醯)一 2—苯基一卢一丙胺醯基〕一|8-丙胺酸,呈水合物(
(4: 1 ) ,m · p . 276 C,得自 N —〔 N -〔對位一〔D L -N-〔(苄氧基)羰基〕申脒基〕苄醯〕一2 —苯基一 卢一丙胺醯基〕一/3 —丙胺酸苄基酯。‘ 起始的酯,m. p . — 174 °C,如下製備: ⑻DL — 2 —苯基一 Θ —丙胺酸於第三,丁醇及氫氧化鈉 -溶液中,與二碳酸二一第三,丁基酯反應,_生成D Ι^·Ν— (第三,丁氧羰基)一2—苯基一卢一丙胺酸,m.p· 147 - 148 °C 0 (b)於解離保護基後,產物於二氯甲烷/水/碳酸氫鈉中 與對位一甲脒基苄醢氯反應,再與氯甲酸苄酯反應,生成 起始的酯。 實例30 雉濟部中央》準扃印长 {請先W請背面之.注意事邛再填寫本页) 類似實例8,DL — N —〔N —(對位一甲脒基苄醯基) 一卢一丙胺醯基〕一 2 —甲基一 /3 —丙胺.酸以水合物 (3:1 ) ,m.p. > 300°C,得自 N —〔N -〔對位一〔 N—〔(苄氧基)羰基)甲脒基〕苄醯〕一Θ—丙胺醯基 〕—DL — 2 —甲基二j 一丙胺酸苄酯。 起始的酯,m· p . 159 — 160 °C,如下獲得: ⑻N -(第三,丁氧羰基)一々一丙胺酸與〔DL〕_2 —甲基一/3 —丙胺酸苄酯偶合,生成DL~_N —〔 N —(第 f 4(210X 297 7发) -44 - 219928 A6 ____ B6 五 '發明說明(43) Ξ,丁氧搜基)一 |8 —丙胺醣基〕一 2 —甲基一卢一丙胺 酸苄酯,M S : 365 ( 47,M+H )。 ⑽保護基解-離後,產物於二氯甲烷/水/碳-酸氫鈉中與 對位一甲脒基苄醯氣反應,再與氯甲酸苄酯反應,可得起 始的酯。 - 實例31 . 類似實例11,N~〔N —〔〔R) — 1 一(對位一甲脒基 苄醯基)一3—吡咯啶_基〕羰基〕一L-«-天冬胺醯基 〕一 3 —苯基一 L —丙胺酸醋酸塩(2:1 )以水合物 .(3:2 )型式,215.C (m.p.),得自 N —〔 N-(-JC(R) 一 1 一〔對位一(AK(苄氧基)羰基〕甲脒基〕苄醯〕一 3 —吡咯啶基〕羰基〕一 3 —〔(苄氧基)羰基〕一L 一丙 胺睡基〕一 3 —苯基一 L 一丙胺酸千基酷,並經水蒸發及 於乙醇中攪拌。 起始的酯如下製備: ⑻(R)— 1一(第三,丁氧羰基)一 3 —吡咯啶基羧酸 與N —〔 3 —〔(苄氧基)羰基〕一 L 一丙胺醯基〕一 3 一苯基一 L—丙胺酸午醋偶合,生成N—.〔 N—〔〔(R) 經 濟 部 中 採 泽 JS} 印 {請先聞讀背面之_注意事*tB再填寫本頁) —1 一(第三,丁氧搜基.)一3 -吡咯啶基〕羰基〕一3 一〔(苄氧基)羰基〕一L 一丙胺醯基〕一 3 —苯基一 L —丙胺酸午基酷,m . ‘p . 84 — 85 ’C。 (b)於三氟醋酸中除去第三,丁氣羰基後,產物於二氯甲 烷/水/碳酸氫鈉中與對位一甲脒基苄醯氯反應,再與氯 甲酸苄酯反碼,生成起姶的酯,m.p. 144 — 145 °C。 f 4(210X 297 公发) -45- 219928 A6 _ B6 ___ 五、發明説明(44 ) 實例32 - 類似實例7,DL-N—〔N —(對位一甲脒基苄醢基) -卢·一丙胺醯-基〕一 2-苯基一|S -丙胺酸,'-以水合物 (1:1 ) ,m.p. 243 — 245 °C 型式,得自 N-〔 N —〔 對位一〔N —〔(苄氧基)羰基〕甲脒基〕苄醯〕一 /3 — 丙胺醯基〕一 DL — 2 —苯基一 /9 一丙胺酸苄基酯。 起始的酯如下製備: ⑻N —(第三,丁氧·幾基)一2 —苯基一/S -丙胺酸, 小 於丙酮中與苄基溴及碳酸鉀迴流加熱17>時。可得D L- N — _ (第三,丁氧羰基)一2 —苯基一 P —丙胺酸苄基酯” m. p . 58 — 59 °C。 (b)於解離第三,丁氧羰基後,產物於N —(第三,丁氧 羰基)一卢一丙胺酸偶合,生成DL—N —〔 N —(第三f 丁氧幾基)一P —丙胺酸基〕一 2 —苯基一Θ —丙胺 基醋,m.p. 84.5 — 86 °C。 ⑹此再於三氟醋酸中轉化成DL-N —〔 N —(第三,丁 - 氧羰基)一卢一丙胺醣基)一 2 —苯基一卢一丙胺酸苄酯 之三氟醋酸塩。 (d)後者於二氯甲烷./水/碳酸氫鈉中先後與對位一甲月来 基七酿氯及氯甲酸苄酯反應,可生成起始的酯,爪冲· 經濟部中央橾準局印裝 (請先聞讀背面、又注意事項再填宵本页) 165 - 166 °C » 實例33 類似實例11,對位一〔2 —〔〔 N —〔 N _ (對位一甲 脒基苄醯基)一P —丙胺醯基〕一L — « —天冬胺醯基〕 肀 4(210X297 W 发) 一 46 — 219928 A6 B6 五、發明説明(45) _ . 哮基〕乙基〕苯甲酸,以水合物(3:7 ),m.p. 194 — 196°C (甲醇/水)得自對位一〔2 —〔〔3 —〔(苄氧 基、)-羰基〕一-N -〔 N —〔對位一〔N —〔(_芊氬甚)羰 基〕甲脒基〕苄醯基〕一iS —丙胺醯基〕一 L 一丙胺醯基 〕胺基〕乙基〕苯甲酸苄基酯。 起始的酯,m.p. 162 - 163。(:製備如·下:. ⑻對位一(2 —氯乙基)苄酿氯轉化k對位一(2 —氯 乙基)苯甲酸苄酯,NTS : 274 ( 8,Μ )-力丨m # π 一运 利用苄醇及^氯 甲烷中。 ⑹對位一(2 —昼氮基乙基)苯甲酸苄酯,MS :又Si 此利用簦氮化鈉於DMSO中獲得。 中與三苯膦及濃氨水先後反應,生成對位一 基)一苯甲酸苄酯,MS : 226 ( 16, Μ (2,Μ),由 ⑹此於吡啶 M濟部中夹《率A印裴 (2 —胺基乙 CH2NH ) 〇 ⑹對位一〔2 —〔〔3 —〔(苄氧基)羰基〕一 N —( - ·. 第三,丁氧羰基).一L —丙胺醯基〕胺基〕乙基〕苯甲酸 - 苄基酯,m. p · 99 — 100 °C,可由此與N —(第三,丁氧 羰基)一 L — «—天冬胺酸苄酯偶合而得.。 ⑼此於三氟醋酸中,去保.護,再與N —(第三,丁氧羰基 )一卢一丙胺酸偶合,生成對位一〔2 —〔〔 3 —〔(苄 氧基)幾基〕一 N—‘〔. N —(第三,丁氧搜基)一/3 —丙
胺酿基〕一 L 138 — 139 °C 丙胺醯基〕胺基〕乙基〕苯甲酸酯,m.p (f)於三氟醋酸中解離第三,丁氧羰基备,產物於二氯甲 ......................................................^..............................^..............................Sf {請先《讀背面之.注意事ifi再填寫本頁) . f 4(210X2971、发) …47 219928 A 6 ______B6 五、發明説明(46 ) 烧/水/ -碳酸氫鈉中,先後與對位一甲脒基醯氯及氯甲酸 苄酯反應,可得起始的酯。 實例-34 - - · 類似實例7,〔DL— N —〔N—(對位一甲脉基苄醯基 )—卢一丙按醯基一 3 —苯基一纥一丙胺酸可以水合物型 式獲得(3:2 ),m.p. 220Λ:(分解),得自 DL-N-〔N —〔對位一〔N —〔(苄氧基)羰塞〕甲脒基〕苄醯 基〕二/3 —丙胺醯基广一 3 —苯基一丙胺酸苄基酯。 起始的酯,ηι·ρ· 208 °C,如下獲得: _ —(第三,丁氧羰基)一 0 —丙胺酸與DL —·今一 苯基一卢一丙胺酸午基醋反應,生成DL — N —〔N—(第 三,丁氧羰基)一]9一丙胺醯基〕一3 —苯基一# 一丙胺 酸平基醋,m4P* 124.5 — 1.26 °C。 一 (b) DL — N—(卢一丙胺酿基)一 3 —苯基一卢一丙胺酸 苄酯之三氟醋酸塩由此得自三氟醋酸。 (c) 此於二氯甲烷/水/碳酸氫鈉中,以對位一甲脒基苄 醯氣及接下來的氯甲酸ί酯處理,可得起始的酯。 實例35 雉濟部中央搮準馬印裝 t請先聞讀背面之.注意事胡再填寫本页) 類似實例U,〔對位二.〔2 —〔〔 Ν —〔 Ν _ (對位一 甲脒基苄醯)—^一丙胺醢基〕_L— α_天冬胺醯基〕 胺基〕乙基〕苯氧'基·〕醋酸,可以水合物(2:7 )型式獲 得,m.p· 210—'213°C’ 得自(S)—3 —〔〔N —〔對 位一〔N —〔(苄氧基)羰基〕甲脒基〕苄醯〕一 /3 —丙 胺醯基〕胺華〕一N 一〔對位—〔〔(丰氧基〕羰基〕甲 甲 4(210X 297y 发) —48 一 219928 A6 B6 五、發明說明(47 ) • 一 . 笔基〕苯·乙基〕琥珀醯胺酸苄基酯。 起始的酯,m· P · 172 — 174 °C,可如下製備: (a>〔- 2 — C-4 —羥苯基)乙基〕胺基甲酸第三,丁基酯 、溴醋酸苄基酯、及碳酸鉀於丙酮中加熱。可得〔對位— 〔〔(苄氧基)羰基〕甲氧基〕苯乙基〕胺基甲酸第三, 丁 基酯,MS : 385 ( 0.5,Μ ) ° . (b) 於解離第三,丁氧羰基保護基後,產物與Ν —(第三 ,丁氧羰基)天冬胺酸4 —苄基酯偶合,生成(S) — N 一〔對位一〔〔(午氧基)搜基〕甲氧基〕苯乙基〕-"3 一〔1_第三,丁氧基甲醯胺基〕琥珀醯胺酸苄酯,_.,P. 178.5 - 180.5 .C ° (c) 此於三氟醋酸中去保護,再與(第三,丁氧羰基 )_卢一丙胺酸偶合,生成〔2 —〔〔(S)— 2—〔(; 氧基)羰基〕一 1 —〔〔對位一〔〔(苄氧基)羰基〕胃甲 氧基〕苯乙基〕胺甲醯基〕乙基〕胺甲醯基〕乙基〕胺基 甲酸第三,丁基酯,m.p. 123 — 124eC。 (d) 於除去第三,丁氧i基保護基後,產物於二氯甲烷/ 水/碳酸氫鈉中先後與對位一甲脒基苄醯氯及氯甲酸苄酯 反應,生成起始的酯。-. »為36 雉濟部中衣搮泽扃印裴 {請先聞讀背面之·注意事邛再填萁本頁) ⑻280毫克1 一〔 N —(對位一氰基苄醯)一—丙胺 醯基〕一 4 一六氫吡啶基醋酸及i毫升三乙胺於15毫升吡 啶中之溶液,以硫化氫飽和。为小時後,溶液蒸發且殘留 物懸浮於乙酸乙酯/水中V過濾及乾Λ示溶性物質,可得 "" "" —4Q — ' 中 4(210X2977 发) π 219928 A6 ___B6 五、發明説明(48 ) 255毫克釣1 -〔 N -〔對位(硫胺甲醯基)苄醯基〕一 卢一丙胺酺基〕一4 一六氫吡啶基醏酸。 脉150毫克-前軀體於15毫升丙酮中之溶液,,與1毫升甲 基碘在沸騰溫度下加熱3小時。一旦溶液冷却至室溫後, 可沈澱出130毫克的1 -〔 N -〔.對位一〔1 -(甲硫基 )亞胺甲醯基〕苄醯基〕一 /8 —丙胺醯基〕一 4 一六氫吡 啶基醋酸氫碘酸塩(1:1 ) ,m.p. 206'— 207 °C。 ⑹100毫克的1 一 C—N —〔對位一〔1 -(甲硫基)亞 胺甲藜基〕斤醯〕一々一丙胺醯基〕一4 —六氫吡啶基醋 .酸#菸10毫> 甲醇中,保持在沸騰溫度下3小時。經,冷却 至室溫後,溶液過濾,濃縮並以二乙醚處理。沈澱的油於 矽膠RP 18上利用水/甲醇(10 : i >層析,此係在傾去 溶劑之後。可得24毫克的1 一〔 N —(對位一甲脒基苄醢 )—丙胺醯〕一 4 一六氫吡啶基醋酸氫碘酸塩(1QU) ,m · p · 206 *C ° 起始的腈可如下獲得: - 班濟部中夹《導扃印裴 {請先閱讀计面之注意事*Ifi再琪艿本页) ⑻4.96克的4 一氰基苄醣氯及2.67克/8 —丙胺酸,於 450毫升碳酸氫鈉溶液(2% )中以室溫.携拌4小時,混 合物再利用濃硫酸酸,化..(PH 6 )。溶液蒸發,且以乙酸乙 酯i取。有機層乾燥及蒸發,可得殘留物,其中利用二異 丙基醚可生成4.6^5克的N —(對位一氰基苄醯基)一卢 —丙胺酸,m. p · 155 — 157 *C。 (b)將635毫克的N —(對位一氰基苄醯基)一卢一丙胺 酸與540毫克的4 —六氫吡啶基醋酸&备,經矽膠RP 1 8 ^ 4(210^ 297 ^ Μ) — 50 — 219928 A6 ___B6 五、發明說明(49 ) 4以THF -/水(85 : I5 )層析後,可得300毫克的1 一〔 ^一(對位一氰基苄酿基)一P —丙胺酿基〕一 4 一六氫吡 啶基醋酸,M.S : 344 ( M+Η ) +。 實例37 400毫克的4 —〔 Ν —〔對位一甲脒基苄醯基)一卢_ 丙胺醯基〕一1 一六氫吡畊基醋酸第三,丁基酯,於15毫 升二氯甲烷及15毫升三氟醋酸中攪拌。溶液蒸發,殘留物 懸浮於5毫升乙醇,再'谏去不溶的物質。濾液以乙酸乙酯 處理,沈澱物眞空過濾再乾燥。粗製產物於矽膠RP 18上 -利用水層析後可得38毫克的4 一〔 Ν —(對位一甲脒棊苄 醯基)一 Ρ —丙胺醯基〕一 1 一六氫吡畊基醋酸三氟醋酸 塩(5:8 ) ,m. p · 157 — 158。<:。 起始物質可如下製備: - ⑻2.23克的N —苄氧羰基一卢一丙胺酸與2.58克吡D井 偶合。蒸發的殘留物懸浮於THF,不溶物質璩去,璩液蒸 發。殘留物於矽膠RP 18上利用水/甲醇(2 — 5 % )層 析,可得2.51 克的〔2—( 4 一六氫吡啡基羰基)乙基 〕胺基甲酸苄酯,MS : 291 ( Μ+·)。
班浒部中央煤璆Λ印$L {請先«請背面之¼意事颏再填寫本頁) (b) 600毫克的前觴體-,.0。3毫升的溴醋酸第三,丁基酯 及25毫克的硫酸氫四丁銨,溶於10毫升甲苯中,再與10毫 升50%強度之氫氧化鈉溶液攪掸1小時。有機層以水洗再 蒸發。殘留物於矽膠上以乙酸乙酯/甲醇(9:1 )層析, 可生成48〇毫克的4 -〔N —〔(苄氧基)羰基〕一/3 — 丙胺醯基〕一 1 _六氫吡畊基醋酸第三\ 丁基酯,MS: f 4(210X 297-a -51 - 雉濟部中央煤箏扃印裝 219928 A6 __ B6 五 '發明説明(50 ) 406 (M+H )+。 ⑹前軀體於乙醇中氫化1小時,其中有200毫克Pd/C 之存·在。濾出-催化劑,濾液蒸發。可得290毫_克的一卢一 丙胺酿基_ 1 一六氣批D井基醋酸第三,丁基醋,_MS: 271 (M+ )。 - ⑹前軀及341毫克的對位一甲脒基苄醯氯,.於20毫升 二氯甲烷及10臺升飽和的碳酸氫鈉中攪知。有機相分出並 蒸發·,殘留物懸浮於乙尨乙酯中。眞空過濾,並乾燥晶體 可得400毫克的4 —〔 N —(對位一甲脒基苄醯基)_卢 -一丙胺醯基〕一 1 —六氫吡畊基醋酸第三,丁基酯, _ , :418 ( M+H )+。 實例38 類似實例37,1.6克的N —〔 N —〔 N —(對位一甲脒 基苄醯)一 iS —丙胺醯基〕_3 —(第三,丁氧羰基)一 L 一丙胺醣基〕一 L 一知|胺酸第三,丁基酯去保護基。粗 製產物於矽膠RP 18上利用水/ THF ( 95 : 5 )層析,可 得867毫克的N_〔 N —〔 N —(對位一甲脒基苄醯基) —丙胺醸基〕一L-α —天冬胺醢基〕一 L 一知1胺酸 三氟醋酸酯,m.p.162 — 163 ·(:。 起始的酯可如下製備:- ⑻N —苄氧羰基一L — α —天冬胺酸第三,丁基酯友L ―寒發胺酸第三,丁基酯塩酸塩偶合,生成Ν—ΓΝ—〔( 苄氧基)羰基〕一 3—(第三,丁氧羰基)一 L_丙胺酿 基〕一L —胺酸第三,丁基醋,m. p . 75 eC (d)。 ......................................................it..............................ir..............................ί*. {請先聞讀背面之注意事颂再填寫本页) · f 4(210X 297乂屑) -52 - 219928 A6 B6 五、發明說明(51) (b)聛類似實例37c般去保護,可得N-〔 3 —第三,丁 氧羰基)一L-丙胺醯基〕一L —托|胺酸第三,丁基酯, m .'p-. 71 °C 0 · ⑹2.8克的前軀體與1.78 克的N —〔(苄氧基)羰基 〕一 P —丙胺酸偶合,粗製產物於矽膠上以乙酸乙酯層析 ,可得2.24克的N_〔N —〔N —〔(苄氧基)羰基〕 一卢一丙胺醯基〕一(第三,丁氧羰基)一 L —丙胺 酿基’〕一 L —絲胺酸第三,丁基酯,m.p. 126°C。 ’⑹2.2克前軀體類似實例37 (c)般去保護,可生成1.61 克的N -〔 N —卢一丙胺醯基一3 -(第三,丁氧羰·基) 一 L 一 丙胺醯基〕一 L 胺酸第三,丁基酯。 ⑹1克的對位一甲脒基苄醯氯與1.61克的前軀膣,依 據步驟37⑹反應,可生成1.62克的起始的酯。 一 實例39 級濟部中央棣準馬印製 {請先聞讀背面之注意事邛再瑱寫本頁) 類似實例37,1.4克的N —〔N —〔N—(對位一甲脒 基苄醯基)一 i9 一丙胺醯基〕一 3 —(第三,丁氧羰基) —L 一丙胺醣基〕一 3 —(對位一第三,丁氧基苯基)一 L —丙胺酸第三,丁基酯,去保護基。產.物懸浮於乙醇中 ,不溶物質過濾,減.液,以.乙醚處理。眞空過濾並以20毫升 異丙醇/乙醇(1:1 )洗滌沈澱物後可得801毫克的N — 〔N —〔 N —(對位·一甲脒基苄醯基)一 /3 —丙胺醯塞〕 —L — α—天冬胺醯〕一3 —(對位一羥苯基)一 L—丙 胺酸三氟醋酸塩(2:5 ) ,m.p. 202 — 204 °C。 起始的醋如下製備: 甲 4(210X 297y;¥) —53 — 219928 A6 B6 五、發明説明(52 ) —⑻.N — -〔( 9 Η — 9 一基氧基)療基〕一3 —(第 三,丁氧羰基)一L 一丙胺酸及3 —(對位一第三,丁氧 基苯·基)一 L——丙胺酸第三,丁基酯偶合,生,成Ν —〔 Ν 〔(9Η ) — 9 基氧基)羰基〕一3—(第三,丁 氧羰基)一L -丙胺醯基〕一 3—(對位一第三,丁氧基 苯基)一 L 一丙胺酸第三,丁基酯及5毫升六氫吡啶,反 應溶液蒸發。殘留物懸浮於甲醇中,不溶物濾去。濾液蒸 發,並於矽黪上利用乙酸乙酯層析。可得2克的3 —(第 三,丁氧基苯基)一Ν —〔 3—(對位一第三,丁氧羰基 )一 L 一丙胺醯基〕一 L 一丙胺酸第三,丁基酯。 < * ⑹前軀體與0.96克的Ν —苄氧羰基一卢一丙胺酸偶合 ,粗製產物於矽膠上利用乙酸乙酯層析,可得2.23克的 )羰基〕一Ρ—丙胺醯基} L—丙胺醯基〕一 3—(對 Ν —〔Ν —〔Ν —〔(苄氧基 一3—(第三,丁氧羰基)一 {請先閱讀背面之注意事項再填寫本頁) •装· .打· 組 濟 部 中 央 採 局 印 位一第三,丁氧基苯基)一L—丙胺酸第三,丁基酯, MS : 670 ( M+H )+。 ⑹2.1克的前軀體如實例37 (c)般去保護,可生成1.67 克的N —〔 N — /3—丙胺醣基〕一 3 —(.第三,丁氧羰基 )—L —丙胺醯基〕一·—(對位一第三,丁氧基苯基) —L 一丙胺酸第三,丁基酯,MS:536(M+H)+。 ⑼1.5克的前ΐί體與0.6克的對位一甲脒基苄醯氯,如 實例37 (d)般偶合,生成1.6克的起始的酯,M S : 682 (Μ + Η )+。 實例40 ' .綠· 甲 4(210X 297^:^) -54 - ^19928 A6 B6 五、發明説明(53) ·. (請先聞磺背面之注竞事项再填寫本页) 類料實·例24,自相當的酯可得N-〔N_〔N —〔(5 —甲脒基一 2 —吡啶基)羰基〕一丙胺醯基〕一L — α —-天冬胺酿基〕一3 —苯基一 L —丙胺酸,.m.p. 222 一 223 *C (分解)。 起始的酯如下製備: ⑻N —〔 3 —〔(苄氧基)羰基〕一 N —〔 N —(第三 ,丁氧羰基)一/9 一丙胺醯基〕一L 一丙胺醯基〕一3 — 苯基二L 一丙胺酸苄酯支保護,並與5 —氰基一 2 —吡啶 羧酸偶合,生成N_〔3 —〔(苄氧基)羰基〕一N —〔 -N-〔( 5-氰基一2—吡啶基)羰基〕一/ —丙胺睡基 〕一L —丙胺酵基〕一3 —苯基一L —丙胺酸平酷,m.p. 157 - 158 *C ° (b)前軀體轉化成N_〔 3_〔(苄氧基)羰基〕一 N, 〔N_〔〔5—(硫胺甲醯基)_2 —吡啶基〕羰基〕一 卢一丙胺酿基〕一L 一丙胺酿基〕一 3 —苯基一 L 一丙胺 酸苄基酯,m.p. 131 - 132 ·<:,如實例36⑻一般。 經濟部中央搮準馬印裝 ⑹前軀體如實例36⑹:^⑹般,轉化成N —〔 3 —〔(午 氧基)稷基〕一Ν —〔 Ν —〔〔 5 —〔 Ν.—(第三,丁氧 幾基)甲脉基〕一 2.—批胺基〕幾基〕一0 —丙胺酷基〕 —L 一丙胺醣基〕一 3 —苯基一 L 一丙胺酸苄基酯,MS :779 ( 11,M + Η )。
實例A 式I化合物可以本身已知的方式當做活性化合物使用, 產製以下組成物之錠劑: 55 甲 4(210X 297 公;^ 219928 A6 B6 五、發明說明(54 )
活性化合物 微晶-體織維素-玉米粉 滑石 羥丙基甲基纖維素 實例B 每錠 200毫克 155毫克 25毫克 25.毫克 20毫克. 425毫克 式I化合物可以本身已知的方式當做活性化合物 產製下列組成物之膠囊劑: 每 錠 用以 活性化合物 玉米粉 乳糖 滑石 硬脂酸鎂 100.0毫克 20.0毫克 95.0毫克 4.5毫克 0.5毫克 200.0毫克 ......................................................it..............................tr.............................if {請先Μ讀背面之注意事is再瑱駕本页) 雉濟部中央橾準局印装 甲 4(210X 297公发) —56 —
Claims (1)
- 史 < V 久 | 專(8 Λ·本 正 ,,修 ¢11 /r範 Λ到 y專 ;^請 ?! ο·' 手 ABCD 六、申請專利範圍 219928 -種具下式之醋酸衍生物 H2N (NH)C-X-Y-CO-Z-CH(Q1 )cooq2 ⑴ 其中… ' - 0/是氫、甲基或苯基, ' 0_2是氣、苯基-c 烧基或Cp 4烧基,.其可在生理條 件下裂解, · X是1,4- 一伸苯基,1,4 —伸六氫吡啶基,經由4 一位 置上之c原子鍵結SY基團,或2,5 —或3,6 —伸吡啶 基, Y是具下式之基團 -(CH2)〇-2-CONHCH(Q3)(CH2)i-3- -CONHCHsCHCQ^)- -(CH2)2NHCOCH2- -NHCO(CH2)3- (Y1) (Y2) (Y3) (Y4) (請先閱讀背面之注意寧項再填窝本頁) O(Y5) 〇 \\ (Y6) 〇 ,cs) /, i —r * - .(Y7) 甲 4「210X297公贷) 57 — 219928 7 7 7 7 ABCD 六、申請專利範面 0Λ是氫、甲基、苯基、-COOH或 •CONH(CH2)2-COOH , 'Q4是氫、-甲基或苯基, - Z是1,4 一伸六氫吡畊基,1,4 一伸六氫吡啶基,經由 1 一位置上之N —原子鍵結至C0基團,或具下式之基團: -NHCH^R1)-或-NHCH(COR2)- · ' R1是氫2甲基、苯基或-COO- Ci_4烷基, R2·是α —胺基羧酲基團,經由胺基鍵結,或為其醏或越胺 ,或具下式之基團-NHCH2C02-Ar,或者 -COR2是一個任意地單或二一 C广,焼化;^胺甲酿$., 或吡咯啶醯基或六氫吡啶醯基, Ar是苯基或可被下列取代之苯基烷基,C,-4烷 氧基、-COOH、-COO—C,-4 烷基、-0(CH2) η -COOH 或 -OCCHOh^-COO· C:-4烷基, 及其水合物及生理上可利用之鹽類。 2.根據申請專利範圍第1項之化合物,其具下式 H2N(HN)C-X - Y*-GONHCH(R11)CH2COOi2.21 I -A 其中 —— X是1,4 -伸苯基或1,4 —六氫吡啶基,經由4 —位置 上之C原子鍵結至Y·基團, Y·是具下式之基團 甲 4 (210X297公釐) —58 — ...................................................^..........................^...........................球' (請先閲讀背面之注意事項再填窝本頁) 219928 7 7 7 7 ABCD 六、申請專利範团 ---(CH2)〇-rC〇NHCH(Qa)(CH2)i.2--(CH2)2NHCOCH2--NHCO(CH2)3->〇 0/是氬事苯基, R1'1是氧或-CO-R2% R22是《—胺基羧酸基團,經由胺基鍵結或為其醏或醯 胺,旦 0;21是氫或烷基,其可在生理條件下裂解, 及其水合物及生理上可利用之鹽類。 3.根據申請專利範圍第1項之化合物.,其中X、z、0/ 及具有申請專利範圍第1項中所示之定義,且γ是 具式Y1之基圃,特別是下列之一者 -CONH(CH2)2_4-, — -CH2CONH(CH2)2-, -CONHCH(C6H5)CH2-/ -CONHGH(CONHCH2CH2COOH)CH2-, _ -GONHCH(CO〇H)CH2- ’ " :C〇MHCH(CH3)CH2-· * X •4.根據申請專利範圍第1項之化合物,其中X、Y、〇/ 及0/具有申請專利範圍第1項所示之意義,且Ζ是下 式基團:-NHCH2-,-NHCH(CH3) - » -NHCH(C6Hs )- (ΥΠ) (Υ3) (Υ4) (Υ51) ...................................................装...........................tr...........................線. (請先閲讀背面之注¾¾再填寫本頁) 甲 4 (210X297公釐) 一 59 — 219928 ABCD 六、中請專利範因 一,_NHCH(COO-異丁基)·、-NHCH(CO-VaL)-, -NHCH(CO-Phe) - ,-NHCH(CO-Tyr)-,-NHCH(CO-Ser -•OC2Hs) -,-NHCH(CG-Leu-0-異丙基)--, -NHCH(CONHCH2CH2 -C6H4 -OCH3 ) -,-NHCH(CONHCH2 CH2 -C,H4 -COOH) - 5 -NHCH(CONHCH2CH2 -CeH,-OCH2COOH) -,-NHCH(CONH2)-或·NHCH (吡咯'啶醯 基) 5. 根據申請專利範圍篥2項之化合物,係選自: N-〔N-〔 4—(對位一甲脒基苄醯胺.基)丁薩:0 — L — α —天冬胺酿〕一L —炎|胺酸, Ν —〔 Ν —(對位一甲脒基苄酿基)一 /3 —丙胺醯基〕 一卢一丙胺酸,及特別地_ - Ν —〔 Ν —〔 Ν —(對位一甲脒基子酵基)一 Θ —丙胺 醯基〕一L 一《—天冬胺醯〕一 3 —苯基一 L —丙胺酸。 ·· 、 6. 根據申請專利範圍第2項之化合物,係選自: -— Ν —〔Ν —〔Ν —( 1—甲脒基一 4 —六氫吡啶基羰基 )—/3 —丙胺酿基.〕.,一.L 一 α —天冬胺酿基〕一3 —苯 基一L —丙胺酸, · Ν —〔 Ν —〔 Ν — ·(對位一甲脒基苯基乙醯)一冷一丙 胺酿基〕一 L—α —天冬胺酿基〕一 3 —苯基一L —丙 胺酸, * « N —〔 NT〔 4—(對位一甲脒基苯基胺甲醯基)丁醯 ...................................................裝...........................ίτ...........................線· (請先閲讀背面之注意事項再填窝本頁) 甲 4 (210X297公釐) —60 — 219928 ABCD 六'申請專利範面 -〕—L -一 α —天冬胺酿基〕一3 —苯基一 L —丙胺酸, Ν-〔Ν—〔(對位一甲脒基苯基胺甲醯基)乙醯〕— L α —天-冬胺酿基〕一3 —苯基_ L ~丙-胺酸, 外消旋一Ν —〔 1 一(對位一甲脒基苄醯基)一 3_六 氫吡啶基羰基〕一Ρ —丙胺酸, N~〔 4 一(對位一甲脒基苄醯胺基)丁醯〕—丙 胺酸及_ N —〔(DL) — N二'(對泣一甲脒基苄醯基)一 3 —苯 基一/3 —丙胺醯基〕一$ —丙胺酸。 -7.根據申請專利範圍第i項之化合物,係選自: Ν —〔 Ν —〔 N—(對位一甲脒基苄醯基)一卢―丙胺 醯基〕一L — a —天冬胺醯基〕一 L —百胺酸異丙基酯, Ν —〔 N —〔 N—(對位一甲脒基苄醯基)―卢一丙胺 醏基〕一L 一《 —天冬胺醯基〕一 L —為|胺酸, N -〔 Ν —〔 N —(對位一甲脒基苄醯基丙胺 醯基〕一 L — a—天冬胺醯基〕一3—(對位一羥苯基 )一 L 一丙胺酸, . N 一〔 N _〔 5 —,(對位一甲脒基苄醯胺基)戊醯〕一 · L — « —天冬胺醯基:r二3 —苯基一 L —丙胺酸, N —〔 5—(對位一.甲脉基平_胺基)戊醋〕一L — a 一天冬胺酸異丁基酯, N —〔 N —〔 N —(對位一甲月米基苄醯基.)一卢一丙胺 ^ · 醯基〕一 L-α —天冬胺醯基〕一 L —絲胺酸乙基酯, ...................................................裝...........................tr...........................線· (請先Η讀背面乏注意字項再填窝本頁) 甲 4 (210X297公釐) —61 一219928 A7 B7 C7- _D7_ 六、申請專利範圍 S' · N —〔N —〔〔(R)_ 1 —(對位一甲脒基苄醯基)一 3 —批略唆基〕搜基〕一L — « —天冬胺蓮"基〕一3 — 苯基一L 一丙胺酸。 8.根據申請專利範圍第· 1項之化合物,係選自: Ν,.Ν' —〔〔(S) -(對位一甲脒基苄醯胺基)伸乙基 〕二羰基〕二一 /9 —丙胺酸, •2 — Ν—(對位一甲脒基苄醯基)一4 — Ν —( 2 —羧 — 乙基)一L —精胺酸, 丨··’· Ν —〔 5 —(對位一甲脒基苄醯胺基)戊醯〕一/3 —丙 胺酸, 外消旋一Ν —〔.〔 1_〔3 — ( 1—甲脒基一4 —六逢 :吡啶塞)丙醯基〕一3 —六氫吡啶基〕.羰基〕一Θ —丙胺 酸’- Ν -〔〔( S ) —· 1 一 ϋ對位一甲眯基苄醯基)一2 —批 咯啶基〕乙醯〕一Θ—丙胺酸, _ (S) — 3,〔〔 Ν —(對位一甲月来基苄醯基)一々一丙 暌醯基〕胺基一3 —/’〔/(對位一甲氧基苯乙基)胺甲醯 基〕丙酸, , N -〔〔(f〇 - 1-(對位一甲脒基苄醯基)一3 -吡 咯啶基〕羰基〕一 /9 一丙胺酸, Ν —〔 N —(對位一曱肤基苄醯基)一2 —甲基一P — • « 丙胺醯基〕·一 L — α —天冬醯胺, 甲 4 (210X297公釐) 一 62 — ...................................................裝...........................tr...........................線. (請先閲讀背壬之注意辜項再填窝本頁) 219928 A7 B7 C7 ________ DT_ 六、申請專利範困 (請先閲讀背面之注意事^再埃窝本頁) N -〔-N —〔(對位一甲脒基苯基)乙醯基〕一/3 —丙 胺醯基〕一P —丙胺酸, 外消旋一N.—〔〔〔 1 —(對位一甲脒基苯基)乙醯〕 ~ 3 —六氫吡啶基〕羰基〕一 # —丙胺酸苄基酯, 外消旋一 N —〔 〔 1 一〔(對位一甲脒基苯基)乙醯〕 六氫吡啶基〕羰基〕一 0 —丙胺酸,. N —〔 N_—〔N —〔 3— ( 1—甲脒基一 4 一六氫吡啶 基’)丙酿〕一丙胺酸基〕一L — α —天冬胺酷基〕 苯基一 L —丙胺酸, - (S)~卢一〔〔DL-N —(對位一甲月米基—苄醯基)·一 3 ~甲基一 /3 —丙胺醯塞〕胺基〕一 r 一氧基一1—吡咯 唆丁酸, · .訂. DL — N —〔N —(對位一甲脒基苄醯基)一0 —丙胺醯 基〕一3 —甲基一卢一丙胺酸, .線. N —〔DL-N —(對位一甲脒基苄醯基)一 2 —苯基一 卢一丙胺醯基〕一P —丙胺酸, DL-N —〔 N —(對位一甲脒基苄醯基)一 0 —丙胺醯 基〕一2 —甲基一卢一丙胺酸, D L ~ N —〔 N —(.對位.一甲脒基苄醯基)一/3—丙胺醯 基〕一2 —苯基一Θ —丙胺酸, 對位一〔2 —〔’〔 N —〔 N —(對位一甲脒基苄醯基) —丙胺醯基〕一L — α —天冬胺醯〕一胺基〕乙基 〕苯甲酸, DL—Ν —〔. Ν —(對位一甲脒基苄醯基)一0 —丙胺醯 甲 4 (210X297公釐) 一63 — 7 77 7 ABCD 六、 —4 219928 申請專利範团 華’ 3-—苯基一—丙胺酸’ 〔對位一〔2—〔〔N —〔N—(對位一甲脒基苄醯基 、)-〜/9 —丙胺醯基〕一 L — α —天冬胺醯〕-胺基〕乙基 〕苯氧基〕醋酸, 1〜〔Ν —(對位一甲脒基苄醯基)一卢一丙胺酸基〕 六氫吡啶醋酸 4 —〔 Ν_—(對位一甲脒基苄醯基)一/3 —丙胺酸基〕 〜1 一六氫吡畊基醅酸,及 Ν —〔Ν —〔Ν_〔( 5 —甲脒基一2 —吡啶基)羰基 〕—戶一丙胺醯基〕一L — 天冬胺醯基〕一 .3 -苯 基—L —丙胺酸。 9·—種具下式之醋酸衍生物 >Y-CO-Zr -CHCQ,1 ) - coo-Q.2 ][' 〆 其中X’是苯基或4 —六氫吡啶基,在4 —位置上被任意 經保護的甲脒基-C(NH)NH-Z,C(NH)NH-B〇c或 CCN-B〇c〇NH-B〇c所取代,且γ、z、Q1及Q2具有申 請專利範圍第i項之相同定義,分子含有至少—個容易 被裂解之蜡基困、苄基-0C0或第三丁基_〇c〇或經保蠖 的甲脉基部H)NH-Z,C⑽)朗如或⑽匆勝⑽ 10.根據申請專利範圍第1 — 8項中杯 ^ Η m 只中任—項疋化合物,當做票學 舌1±化合物,用以治療或預防 於枯著性蛋白質结合至 血小板或血小板裝集所致之疾 、 , . .. . ^ 特別疋用以治療或預 防血小板栓塞、血栓形成、 柱篆、心肌梗塞、發炎或 ............................................^.............................. ............................參 (請先W讀背兩之注意事項再壤駕本頁) —^4- '― 219928 A7B7C7D7 六、申請專利範团 動脈硬化。 其 11· 一種製備根據申請專剎範圍第1項之化合物之方法 特徵在於: ⑻移除下式化合物之至少一個保讀基 X,- Y-CO-Z,-CH(Q_l )-COO-QZ 其中' · —.及Y具申請專利範圍第1項所示之意義, X’是苯基或4 —六氫吡啶基,其可在4 一位置上玻 ' -任意保護的甲脒基所取代,且 · 相 ..............................................装…. Γ靖先¾¾背负之注意事if再填駕本/〇〇 Z及〇/具有_申請專利範圍第1項中與z及 同之定義,或者. • . ⑼骑下式腈中之腈基團轉化成甲脒基團 .- ;^c-Q-y-c〇:z-cHfe>cco-Q^ (in, 4. 且,必要時將式I化合物轉化成生理上可耐受之塩,或骑式 1化合物之塩轉化成游離態酸或鹸。 12· —種用以治療由於粘著性蛋白質結合至血小板或血小板 聚集所致疾病之禁學組合物,其中含洧根據申請專利範 圍第1或2項之化合物為活性化合物。 一 甲4(210x297公幻 一 修219928 _____—-----------— 第80101540號專利申講菜 中文補充說明軎U2年3月) (:17[12:^404.1/2}120(分子量 355.40) Ν 15.77 計算值:C 57.45 Η 6.52 Ν 15.71Q αι UJ ID U) 實驗值:C 57.52 Η 6.55 ι\) ru cn —ωωπο HW\0215*G 2 219928 (:2〇[!3^507*2}120(分子量 561.59) 計算值:C 55.61 H 6.28 N 12.47 H20 6.42¾ 實驗值:C 55.55 H 6.38 N 12.31 H20 7.40¾hl.s SEC. M5S· T :-' 00/01/(〇0 00:50:cnacz^n 3>^mcncn ZZ 广 ON II II II II \l 22S2B 3ΓΟ ID 1.-::-^..::--3 nszM 4000301 一 EXT u 57 • C41 5 KBR ?anl;? C3D179· loal 2 HWX0215.G 219928 奮例17 〇24.Η2βΝ 5〇β · 1Η20 (分子 量 501·54) 計算值 :C 57.48 Η 5.82 Ν 13.96 Η2〇 3.5996 實驗值 :C 55.33 Η 6.44 Ν 13.65 η2〇 3.4096oa<z-n 3>"ΠΠ1ϋΗΛ zzraN ii Η Π II H 2Z528 ω2 3¾ 10一 - •:-'--T S<i5 KBRaR.RLIG :-.. CSN = 400410 i EXT Π Is - HWX0215.G *扣說專我黨實例化合物结構式 γ書⑼年β月) f 杳 M k Λ九我—It ^~SL·實例 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 3 1 32 C6H4 C6H4 ;vv C6H4 N-六M 吡啶基^ C6H4 C6H4 C6H4 C6H4 C6H4 C6H4 C5H4 C6H4 N-六氫 吡啶基 C5H4 C6H4 C6H4 C6H4 C6H4 C,H , O 4 C0NH(CH^), 2 4CONHCH(CO-S-Ala)CH2CONHCPUCOOH )CH2 C0NH(CK.), 2 4 ch2ch2con-六gUL啶基. C〇N-吡咯啶基 -CH2 conhch2ch2CONHCH2CH2 CON—吡咯啶基CONHCH2CH(CH3)CH2CONHCH2CH2 ch2com-六氫吡啶基- ch2con-六氬吡啶基CH2CH2CONHCH2CH2 C0NH(CHn ) t 2 4 C〇NHCH(CH3)CH2 CONHCH2CH2 CONHCH2CH2 COUHCHCH(CgH5) CONHCH2CH2 CON-吡咯啶基 C〇H4 d 33 C6H4 conhch2ch2 * 34 C6H4 CONHCH2CH2 35 C〇H4 CONHCH2CH2 36 C6H4 CONHCH2CH2 C6H4 C〇NHCH2CH2 38 C6H4 CONHCH2CH2 39 C6H4 CONHCH2CH2 40 乙-吼啶基c〇nhch2ch2 1 nhTR"(c5h5 ) NHCH(C0NHCH2CH2C6H40 N-六氫吡啶基 六氫吡哄基. NHCH(CO-Val) NHCH(CO-Tyr) NHCH(CO-Phe) NHCH(CO-Phe) nhch2 MHCH2 NHCH2 NHCH2 NHCH2 NHCH (CONfICH2CH2C6H4〇CH3) NHCH(CO-Leu-0-iPr) nech2 幽c敗c〇nh2) nhch2 nhch2 nhch2 . NHCH(CO-Phe) NHCH(C0〇-^TS NHCH(C〇-吡咯啶基 ) nhch(ch3). MHCH(CO-Ser-OC.H NHCH NHCH.C?{(CH.) ' Δ j NHCil ( CO-Phe ) nhch2 nhch(conhch2ch2c6h4cooh) 2 COOH ) H H H H H H fi H H H H H H H H H H H H H H H H 苄基 H H H H H H H H H H H H H H H H H C6H5 H H H H H H H Q‘ 219928 第80101540«専利申籣菜 中立»充雉明翥fsites 阿斯匹靈,ticlopidine及血小板接《GP Ilb-IIIa之邇擇性抑制Μ Ro 43-5054對犬隻活《内栓塞形成之作用。 不穩定之心皎痛主换由血小板依賴性之冠吠》脈栓塞所引起。吾人 HM不穩定心姣痛之犬隻比較三種抗血小板製劑之作用:眄斯匹靈· UcUpidine及Ro 43-5054 。卩〇 43-5054係一霍新顧低分子量胜呔腰 似化合物•可完全且特興地抑制配位结合GP Ilb-IIIa 。於纆樣械傷 害及挟鏞一段冠吠動脈之闋臛犬隻,因進行性血小板栓塞之形成•使 瓖吠冠狀動脈血流波動(CFVs)產生。阿斯匹靈(ASA) (10毫克/公斤靜 脈注射)可增加流血時間(BTH120 土 11s比170 土 60s (SE) n = 6, P, 0.05)並使CFVs消失。然而•短暂之腎上腺索灌注(10微克/分鐮) 可使CFVs再出現*此顯示ASA對CFVs之抑制作用會受兒茶酚胺剌激而 抵消。JiUiclopidine預處理5天(2000毫克/天•口阪)可使BT增加 至187 士 11s (SE, n = 6) ·並防止CFVs之發生•然而•較短或劃悬較低 之預處理則無效。R〇 43-5054可依_量地延長BT,並於1微克/公斤 •分鐘(n = 5)之閥值_量使CFVs消失。該抑制作用不因腎上腺索而消 失*於灌注停止後又出現。吾人玆结綸· Ro 43-5054於犬隻中偽一較 ASA或ticlopidUe更有效之抗栓塞劑•可用於不穩定心狡痛。 CHX153.G
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH77590 | 1990-03-09 | ||
CH11591 | 1991-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW219928B true TW219928B (zh) | 1994-02-01 |
Family
ID=25683562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW080101540A TW219928B (zh) | 1990-03-09 | 1991-02-27 |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0445796B1 (zh) |
JP (1) | JP2501252B2 (zh) |
KR (1) | KR910016765A (zh) |
AT (1) | ATE167482T1 (zh) |
BR (1) | BR9100941A (zh) |
CA (1) | CA2037153A1 (zh) |
DE (1) | DE59109010D1 (zh) |
ES (1) | ES2118067T3 (zh) |
FI (1) | FI911148L (zh) |
HR (1) | HRP930353A2 (zh) |
HU (1) | HUT56582A (zh) |
IE (1) | IE910778A1 (zh) |
IL (1) | IL97401A (zh) |
IS (1) | IS3681A7 (zh) |
MC (1) | MC2221A1 (zh) |
MX (1) | MX24811A (zh) |
MY (1) | MY105375A (zh) |
NO (1) | NO301167B1 (zh) |
NZ (1) | NZ237269A (zh) |
PH (1) | PH30963A (zh) |
PT (1) | PT96983B (zh) |
RU (1) | RU2072359C1 (zh) |
TW (1) | TW219928B (zh) |
UY (1) | UY23197A1 (zh) |
ZA (1) | ZA911534B (zh) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5332726A (en) * | 1989-09-29 | 1994-07-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic peptides and pseudopeptides |
US6017877A (en) * | 1990-04-06 | 2000-01-25 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US6521594B1 (en) | 1990-04-06 | 2003-02-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5780303A (en) * | 1990-04-06 | 1998-07-14 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5545658A (en) * | 1991-03-26 | 1996-08-13 | Hoffman-La Roche Inc. | Amino acid derivatives |
UA39849C2 (uk) * | 1991-03-26 | 2001-07-16 | Ф.Хоффманн-Ля Рош Аг | ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ |
AU661659B2 (en) * | 1991-04-11 | 1995-08-03 | Rhone-Poulenc Rorer International (Holdings) Inc. | Anti-thrombotic peptide and pseudopeptide derivatives |
ATE142641T1 (de) * | 1991-05-13 | 1996-09-15 | Fujisawa Pharmaceutical Co | Neue peptid-verbindungen und verfahren zur herstellung davon |
US5220050A (en) * | 1991-05-17 | 1993-06-15 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
US5254573A (en) * | 1991-10-15 | 1993-10-19 | Monsanto Company | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors |
US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
US5625093A (en) * | 1991-10-15 | 1997-04-29 | G. D. Searle & Co. | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors |
CA2115848A1 (en) * | 1991-10-15 | 1993-04-16 | Philippe Roger Bovy | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors |
WO1993012103A1 (en) * | 1991-12-13 | 1993-06-24 | G.D. Searle & Co. | Phenyl amidines lactones useful as platelet aggregation inhibitors |
US5424334A (en) * | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
US5227490A (en) * | 1992-02-21 | 1993-07-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1993018058A1 (en) * | 1992-03-06 | 1993-09-16 | G.D. Searle & Co. | Peptides mimics useful as platelet aggregation inhibitors |
HUT63609A (en) * | 1992-03-10 | 1993-09-28 | Sandoz Ag | Process for producing new derivatives and isosters of beta-amino acids and pharmaceutical compositions comprising such compounds |
AU4540693A (en) * | 1992-06-25 | 1994-01-24 | G.D. Searle & Co. | Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors |
US5272162A (en) * | 1992-07-02 | 1993-12-21 | G. D. Searle & Co. | Platelet aggregation inhibitors |
US5354738A (en) * | 1992-09-04 | 1994-10-11 | G. D. Searle & Co. | Platelet aggregation inhibitors |
AU675689B2 (en) * | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH08505846A (ja) * | 1992-12-29 | 1996-06-25 | スミスクライン・ビーチャム・コーポレイション | 血小板凝集阻害用化合物 |
DE4301747A1 (de) * | 1993-01-23 | 1994-07-28 | Cassella Ag | Substituierte Aminoverbindungen, ihre Herstellung und ihre Verwendung |
US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
US5409939A (en) * | 1993-02-12 | 1995-04-25 | G. D. Searle & Co. | Phenyl amidine thio derivatives useful as platelet aggregation inhibitors |
US6268380B1 (en) * | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
AU6267894A (en) * | 1993-03-02 | 1994-09-26 | G.D. Searle & Co. | N-acyl beta amino acid derivatives useful as platelet aggregation inhibitors |
ZW4194A1 (en) * | 1993-03-29 | 1994-12-21 | Zeneca Ltd | Heterocyclic compounds |
DK0825184T3 (da) * | 1993-03-29 | 2001-09-10 | Astrazeneca Ab | Heterocykliske derivater som blodpladeaggregeringsinhibitorer |
US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
US5750754A (en) * | 1993-03-29 | 1998-05-12 | Zeneca Limited | Heterocyclic compounds |
US5652242A (en) * | 1993-03-29 | 1997-07-29 | Zeneca Limited | Heterocyclic derivatives |
US5612355A (en) * | 1993-06-23 | 1997-03-18 | G. D. Searle & Co. | Phenyl amidine lactones useful as platelet aggregation inhibitors |
US5463011A (en) * | 1993-06-28 | 1995-10-31 | Zeneca Limited | Acid derivatives |
GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
GB9313285D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Acid derivatives |
US5430043A (en) * | 1993-08-24 | 1995-07-04 | G. D. Searle & Co. | Platelet aggregation inhibitors |
CN1041919C (zh) * | 1993-09-22 | 1999-02-03 | 藤泽药品工业株式会社 | 用作血小板激活因子拮抗物的N-(3-哌啶基碳酰)-β-氨基丙酸衍生物 |
US5780590A (en) * | 1993-10-15 | 1998-07-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
US5523302A (en) * | 1993-11-24 | 1996-06-04 | The Du Pont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
US5446056A (en) * | 1993-11-24 | 1995-08-29 | The Du Pont Merck Pharmaceutical Company | Isoxazoline compounds useful as fibrinogen receptor antagonists |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
CN1167485A (zh) * | 1994-11-01 | 1997-12-10 | 泰尔茂株式会社 | 四氢异喹啉衍生物和含有它们的药物制剂 |
WO1996019475A1 (en) * | 1994-12-22 | 1996-06-27 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
JP3874455B2 (ja) * | 1996-06-27 | 2007-01-31 | 新日本製鐵株式会社 | フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤 |
JP3874438B2 (ja) * | 1994-12-28 | 2007-01-31 | 新日本製鐵株式会社 | 置換β−アミノ酸残基を有するフィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤 |
KR19980703107A (ko) * | 1995-03-17 | 1998-10-15 | 후지야마 아키라 | N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도 |
US5811398A (en) * | 1995-04-11 | 1998-09-22 | G. D. Searle & Co. | Platelet aggregation inhibitors containing C-terminal aminergic side chain amino acid residues |
US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
ZA963391B (en) * | 1995-05-24 | 1997-10-29 | Du Pont Merck Pharma | Isoxazoline fibrinogen receptor antagonists. |
IL123164A (en) * | 1995-08-30 | 2001-03-19 | Searle & Co | Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them |
US5942544A (en) * | 1996-02-22 | 1999-08-24 | Dupont Pharmaceuticals Company | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors |
DK0892780T3 (da) * | 1996-02-22 | 2003-03-03 | Bristol Myers Squibb Pharma Co | m-Amidinophenylanaloger som faktor Xa-inhibitorer |
CA2248809A1 (en) * | 1996-03-13 | 1997-09-18 | Fujisawa Pharmaceutical Co., Ltd. | N-[(r)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist |
US5872122A (en) * | 1997-10-16 | 1999-02-16 | Monsanto Company | Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation |
US6066651A (en) * | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
SI0928790T1 (en) * | 1998-01-02 | 2003-06-30 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
US6100282A (en) | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
US6037365A (en) * | 1998-09-25 | 2000-03-14 | G.D. Searle & Co. | Aminobenzamidinosuccinyl lactone derivatives useful as inhibitors of platelet aggregation |
ID28356A (id) | 1998-10-22 | 2001-05-17 | Hoffmann La Roche | Turunam tiazola |
JP2002533406A (ja) | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 新生物の治療における併用療法として、金属プロティナーゼ抑制剤および一またはそれ以上の抗新生物剤を用いる方法 |
GB0019008D0 (en) * | 2000-08-04 | 2000-09-27 | Astrazeneca Ab | Therapeutic compounds |
EP1193248A1 (en) * | 2000-09-30 | 2002-04-03 | Aventis Pharma Deutschland GmbH | Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
US7317019B2 (en) | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3577700D1 (de) * | 1984-11-30 | 1990-06-21 | Shosuke Okamoto | Lysinderivat und proteinase-inhibitor. |
-
1991
- 1991-02-26 CA CA002037153A patent/CA2037153A1/en not_active Abandoned
- 1991-02-27 TW TW080101540A patent/TW219928B/zh active
- 1991-03-01 NZ NZ237269A patent/NZ237269A/xx unknown
- 1991-03-01 ZA ZA911534A patent/ZA911534B/xx unknown
- 1991-03-04 HU HU91186A patent/HUT56582A/hu unknown
- 1991-03-04 IL IL9740191A patent/IL97401A/en not_active IP Right Cessation
- 1991-03-06 MC MC912175A patent/MC2221A1/xx unknown
- 1991-03-07 JP JP3065316A patent/JP2501252B2/ja not_active Expired - Lifetime
- 1991-03-07 RU SU914894657A patent/RU2072359C1/ru active
- 1991-03-07 FI FI911148A patent/FI911148L/fi unknown
- 1991-03-07 ES ES91103462T patent/ES2118067T3/es not_active Expired - Lifetime
- 1991-03-07 EP EP91103462A patent/EP0445796B1/de not_active Expired - Lifetime
- 1991-03-07 MX MX2481191A patent/MX24811A/es unknown
- 1991-03-07 AT AT91103462T patent/ATE167482T1/de not_active IP Right Cessation
- 1991-03-07 MY MYPI91000363A patent/MY105375A/en unknown
- 1991-03-07 DE DE59109010T patent/DE59109010D1/de not_active Expired - Fee Related
- 1991-03-08 IS IS3681A patent/IS3681A7/is unknown
- 1991-03-08 PH PH42106A patent/PH30963A/en unknown
- 1991-03-08 KR KR1019910003736A patent/KR910016765A/ko not_active Ceased
- 1991-03-08 UY UY23197A patent/UY23197A1/es not_active IP Right Cessation
- 1991-03-08 IE IE077891A patent/IE910778A1/en unknown
- 1991-03-08 NO NO910934A patent/NO301167B1/no unknown
- 1991-03-08 PT PT96983A patent/PT96983B/pt not_active IP Right Cessation
- 1991-03-08 BR BR919100941A patent/BR9100941A/pt not_active Application Discontinuation
-
1993
- 1993-03-12 HR HR930353A patent/HRP930353A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL97401A (en) | 1995-03-15 |
HRP930353A2 (en) | 1996-06-30 |
JP2501252B2 (ja) | 1996-05-29 |
HU910186D0 (en) | 1991-08-28 |
NO301167B1 (no) | 1997-09-22 |
DE59109010D1 (de) | 1998-07-23 |
UY23197A1 (es) | 1991-09-04 |
PH30963A (en) | 1997-12-23 |
BR9100941A (pt) | 1991-11-05 |
PT96983B (pt) | 1998-07-31 |
RU2072359C1 (ru) | 1997-01-27 |
KR910016765A (ko) | 1991-11-05 |
MY105375A (en) | 1994-09-30 |
EP0445796A3 (en) | 1991-10-30 |
EP0445796A2 (de) | 1991-09-11 |
EP0445796B1 (de) | 1998-06-17 |
NZ237269A (en) | 1993-05-26 |
PT96983A (pt) | 1991-10-31 |
ES2118067T3 (es) | 1998-09-16 |
CA2037153A1 (en) | 1991-09-10 |
ZA911534B (en) | 1991-11-27 |
ATE167482T1 (de) | 1998-07-15 |
MX24811A (es) | 1993-11-01 |
JPH04217652A (ja) | 1992-08-07 |
NO910934D0 (no) | 1991-03-08 |
MC2221A1 (fr) | 1993-02-02 |
IS3681A7 (is) | 1991-09-10 |
FI911148A0 (fi) | 1991-03-07 |
HUT56582A (en) | 1991-09-30 |
NO910934L (no) | 1991-09-10 |
FI911148L (fi) | 1991-09-10 |
IL97401A0 (en) | 1992-06-21 |
IE910778A1 (en) | 1991-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW219928B (zh) | ||
KR102714781B1 (ko) | 미토콘드리아-표적화 펩티드 | |
RU2097378C1 (ru) | ПРОИЗВОДНЫЕ N-АЦИЛ- α -АМИНОКИСЛОТЫ ИЛИ ИХ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ПРОСТЫЕ ИЛИ СЛОЖНЫЕ ЭФИРЫ, АМИДЫ ИЛИ ГИДРАТЫ И КОМПОЗИЦИЯ ИНГИБИРУЮЩАЯ СВЯЗЫВАНИЕ АДГЕЗИВНЫХ ПРОТЕИНОВ С ТРОМБОЦИТАМИ И АГРЕГАЦИЮ ТРОМБОЦИТОВ | |
RU2607045C2 (ru) | Бензиламиновые производные как ингибиторы калликреина плазмы | |
US5430024A (en) | Peptides bearing N-terminal amidino moieties and their use as inhibitors of platelet aggregation | |
US6797820B2 (en) | Succinate compounds, compositions and methods of use and preparation | |
ES2260036T3 (es) | Derivados de urea como inhibidores del receptor ccr-3. | |
PT92513B (pt) | Processo para a preparacao de novos derivados do acido benzoico e do acido fenilacetico e de composicoes farmaceuticas que os contem | |
WO1999035163A1 (en) | Phenylalanine derivatives | |
US6900179B2 (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | |
BG65755B1 (bg) | Инхибитори на клетъчна адхезия | |
DE4443390A1 (de) | Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten | |
ES2202137T3 (es) | Inhibidores de factor vii a. | |
WO2011025799A1 (en) | Cathepsin c inhibitors | |
JP4927566B2 (ja) | Par−2アゴニスト | |
JP4842254B2 (ja) | Par−2アゴニスト | |
EP0990645A1 (en) | Novel sulfonamide derivatives | |
US20240059734A1 (en) | Mitochondria-targeting peptides | |
LT3681B (en) | N-acyl-alpha-amino acid derivatives, method for producting thereof,pharmaceutical compositions and preparing them | |
HRP930500A2 (en) | Benzoic-acid phenylacetic-acid new derivatives |